



Systematic Review Laser, Intense Pulsed Light, and Radiofrequency for the Treatment of Burn Scarring: A Systematic Review and Meta-Analysis

Yubing Bai^{1,†}, Yiqiu Zhang^{1,†}, Wei Ni^{1,2} and Min Yao^{1,*}

- ¹ Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
- ² Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan 430000, China
- * Correspondence: my058@vip.sina.com
- + These authors contributed equally to this work.

Abstract: Burns and scarring are considered some of the greatest problems in public health because of their frequent occurrence. Today, photo-electric technology shows promising results in the treatment of burn scars. Over the years, more clinical trials and more technologies for scarring have emerged. The aim of this study was to determine better timing and methods of photo-electric therapy for burn scars. This study was registered in PROSPERO (CRD42023397244), following the PRISMA statement, and was carried out in concordance with the PRISMA checklist. In October 2022, we searched PubMed.gov, Embase, and the Cochrane library (1980–present) for published studies related to the photo-electric treatment of burn scars. Two review authors independently selected the studies, extracted the data, assessed the risk of bias among the studies included, and carried out NIH assessments to assess the certainty of the evidence. A third review author arbitrated any disagreements. Our research included 39 studies. We found evidence suggesting that photo-electric therapy between six months and one year offers significantly better outcomes than treatment of scarring after one year. The evidence also suggests the use of IPL for the treatment of early burn scarring. However, it is important to emphasize that the scientific evidence remains insufficient. We need more clinical trials of higher quality and with less heterogeneity to confirm our results.

Keywords: burn scarring; laser therapy; IPL; timing and method of photo-electric therapy

1. Introduction

Burn scars are considered one of the greatest problems in public health [1,2]. Hypertrophic scarring occurs in 30 to 90 percent of patients following burns [3–5]. Most burn patients have to suffer physical pain and pruritus in the first stage. As long-term effects, dysfunction and aesthetic deformations in some severe cases also negatively impact patients' self-confidence, making them feel inferior. Today, first-line therapy for scarring includes surgery, pression therapy, silicone sheets and gel formulations, intralesional pharmacologic treatments, and many others [6-8]. However, the recurrence rate of scars after surgery is high at up to 45–100% [9–11]. Intralesional pharmacologic treatments are also commonly used, including triamcinolone acetonide (TAC) and fluorouracil (FU) [12,13]. Overall, burn scar characteristics can certainly be improved [14–17] but also cause many side-effects. For example, TAC can cause atrophy, hypopigmentation, hypertension, hirsutism, and even Cushing's syndrome [18], and FU may also have myelosuppression activities, causing leukopenia, infection, anemia, and other side effects. Additionally, some treatments cannot obtain satisfactory results. Other methods, including radiotherapy, cryotherapy, and massage therapy, are not commonly used clinically for a variety of reasons [9,19,20]. Meanwhile, photo-electric technology, which shows promising results in the treatment of



Citation: Bai, Y.; Zhang, Y.; Ni, W.; Yao, M. Laser, Intense Pulsed Light, and Radiofrequency for the Treatment of Burn Scarring: A Systematic Review and Meta-Analysis. *Eur. Burn J.* **2023**, *4*, 142–162. https://doi.org/10.3390/ ebj4020013

Academic Editor: Naiem Moiemen

Received: 6 February 2023 Revised: 17 March 2023 Accepted: 17 March 2023 Published: 23 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). burn scars [21], produces photophysical (such as thermal, mechanical, and electromagnetic) and photobiological effects (such as photochemistry and photobiological regulation) by skin exposure.

Today, the increasing interest in photo-electric therapy is making a great difference in the treatment of scarring. Photo-electric therapy in scarring includes pulsed dye lasers (PDLs), neodymium-doped yttrium aluminum garnet (Nd: YAG) lasers, low-level lasers (LLLT), intense pulsed light (IPL), ablative fractional carbon dioxide lasers (CO₂AFL), and radiofrequency (RF). On Pubmed.gov, over two thousand results since 1967 can be found for the photo-electric treatment of scars. However, nearly 1800 of these results were published after the year 2000, and over a thousand were published in the last decade. Thus, in recent years, more clinical trials have been conducted and more technologies for scarring have emerged. These technologies include narrow-spectrum intense pulsed light (DPL) and Q-switched frequency-doubled Nd: YAG lasers. Due to the abovementioned factors, photo-electric treatment has become an efficient modality of therapy for burn scars with few side effects. Some systematic reviews have noted that CO₂AFL is a safe, costeffective, and efficacious procedure for burn scars [22] that offers objective improvements specifically for chronic burn scars [23]. However, systematic reviews of other treatments are still scarce. We located a systematic review about the effectiveness of laser therapy for hypertrophic burn scars; this review noted that the evidence is not adequate to reach a conclusion [24]. Additionally, we found a systematic review and meta-analysis about surgical scars that showed that laser therapy may be a useful modality to minimize surgical scars when applied earlier on [25]. However, this study only used four articles to perform the meta-analysis, so more research should be carried out to support this result. We also found a systematic review of early laser intervention in scarring [26]. The results were uncertain as to whether early laser treatment can reduce scar formation, and more highquality research is needed for a definitive conclusion. There were also some reviews on this topic [27,28]. Globally, there are still many deficits in photo-electric therapy, and no detailed protocol is available. We still have no agreed-upon methods or parameters for the treatment of burn scars, which may cause many side-effects. This study focuses on photo-electric therapy, which can be used in the first period of scarring to prevent progression in a worse direction. We also explore when and how to use these treatments to achieve the most effective outcomes.

2. Materials and Methods

2.1. Search Strategy

Firstly, this study was registered in PROSPERO (CRD42023397244), following the PRISMA statement, and was carried out in concordance with the PRISMA checklist, which is included in the Supplementary Materials (File S1).

We employed the following search strategy to identify the clinical evidence reported in the biomedical literature: In October 2022, we searched PubMed.gov, Embase, and the Cochrane library (1980–October 2022) for published case reports, clinical studies, clinical trials, controlled clinical trials, and randomized controlled trials related to the photo-electric treatment of burns. We included no restriction for language. The mesh terms we utilized were 'burn' AND ('laser' OR 'light' OR 'radiofrequency') AND 'therapy*' AND 'cicatrix'. The details of our search strategy are provided in Table 1.

	Participants	Intervention	Study
Mesh word	burn* AND Cicatrix	(laser* OR light OR radiofrequency) AND therap*	Clinical Study
Free word	(postburn OR 'post burn') AND (Scar OR Scars OR Cicatrization OR Scarring OR 'hypertrophic scar*' OR keloid)	('fractional carbon dioxide' OR 'fractional CO ₂ ' OR 'pulsed dye laser' OR PDL OR Biostimulation OR Photobiomodulation OR 'low level laser' OR LLLT OR 'Neodymium Doped Yttrium Aluminum Garnet' OR er yag OR 'erbium' OR 'nd yag' OR photothermol* OR 'intense pulsed light' OR IPL OR radio-frequency) AND (treatment* OR therapeutic*)	in Humans

Table 1. Search details on PubMed.gov.

* Vocabulary with this root word.

2.2. Selection Inclusion

To be included in the analysis, an original article had to meet the following inclusion criteria: (1) subject: patients who had clinically obvious scars, with more than 50% of the sample featuring scarring due to burns; (2) intervention: treatment of scars needed to involve photo-electric therapy; (3) outcome: Vancouver Scar Scale (VSS) score, Patient and Observer Scar Assessment Scale (POSAS), Visual Analogue Score (VAS), and scar thickness (mm) measured with ultrasonography; (4) control: pretreatment in individuals or other treatments or an untreated area control; (5) study design: randomized controlled trial (RCT), non-randomized control trial, pre–post study of the same person, cohort study, case–control study, and/or comparative study; (6) a mention of scar duration.

The exclusion criteria were as follows: (1) subject: more than 50% of the sample due to etiologies other than burns; (2) intervention: treatment of scars did not involve photoelectric therapy; (3) outcomes: measurement methods did not include the Vancouver Scar Scale (VSS), the Patient and Observer Scar Assessment Scale (POSAS), the Visual Analogue Score (VAS), or scar thickness (mm) measured with ultrasonography; (4) control: no control; (5) study design: case report or case series; (6) no mention of scar duration (Figure 1).




Figure 1. Eligibility of studies for inclusion in the meta-analysis.

2.3. Data Extraction

Two independent investigators browsed all included studies and recorded the features and outcomes of the trials using a data extraction form. The following variables were summarized in a standard Excel file: first author's name, year of publication, study design, control, duration of follow-up, sample size, country, patients' baseline characteristics, the type of treatment, the parameters used, the requirements, whether or not any other scar treatments were used concurrently, and the main outcomes (VSS, total POSAS, POSAS-patient, POSAS-observer, VAS, and thickness). If the study used multiple evaluation data, then our selection order was as follows: (1) total POSAS, (2) POSAS-observer, (3) POSAS-patient, (4) VSS, and (5) VAS and thickness. These instruments are the most widely used and objective assessment criteria for burn scars. We also contacted the corresponding authors for more detailed information when the necessary data were not presented in the original study. Discrepancies between investigators were resolved by discussion and consensus.

2.4. Methodological Quality Assessment of Included Studies

The quality assessment for all studies was performed using the study quality assessment of the National Heart, Lung, and Blood Institute (NIH) [29]. This assessment has different scales for each type of study, with ratings of good, fair, and poor.

2.5. Statistical Analysis

Consensus in China indicates that the length of immature scarring varies greatly between individuals and is dependent on a number of factors. Most scars reach maturity in 6–12 months, but the average immature period for hyperplastic scars can be 22–46 months [30]. As a result, to determine the best time to start treatment and the best method for scar treatment within one year, we analyzed relevant data by dividing the samples into the following groups: scarring for less than six months, scarring for six months to one year, and scarring for longer than one year. We used Review Manager 5.4 to calculate the std. mean difference (SMD) or weighted mean difference (WMD) with a 95% confidence interval (95% CI) for continuous outcomes. As substantial heterogeneity was identified, we used only the random-effects model. A p-value less than 0.05 was judged to be statistically significant.

3. Results

3.1. Identification of Eligible Studies

A flowchart of the literature search process is presented in Figure 1. Our search yielded 349 unique articles. Of these, 46 articles met our inclusion criteria (Figure 1), and 39 articles were available. We found that 12 were cohort studies [31–42], 3 were case–control studies [43–45], 5 were RCTs [46–50], 4 were non-randomized controlled trials [51–54], and 15 were in-patient controlled studies [55–69]. Table 2 summarizes the characteristics of the 39 studies. These studies were published between 2004 and 2020. The population involved mainly burn scars. The studies were of moderate or high quality. Ultimately, we included 22 studies with a total of 916 patients who suffered scarring for over one year, 10 studies with 355 patients who suffered scarring for over 6 months but less than 1 year, and 13 studies with 1101 patients who had scars for up to 6 months.

Author	Year	Study	Control	Follow-Up (Month)	Sample	Gender	Age	Treatment	Other Treatments	Parameter	Device	Outcomes	NIH
		Design		after Final Treatment	Size	(M/F)	(Years)		Combined			Measure	
Alsharnoubi [48]	2018	RCT	UAC	3	15	5/10	4.73 ± 1.79	LLLT	NA	$\Lambda = 632.8 \text{ ED} = 16$	Bbravo terza serie HENE laser (ASA s.r.i)	VSS, ST	GOOD
Douglas [50]	2019	RCT	UAC	1.5	19	15/4	29	UFCL	NA	5% density, 300 Hz, 50 mJ	Ultrapulse, Lumenis	VSS, P-POSAS	GOOD
Ebid [49]	2017	RCT	Placebo control	3	49	30/19	$\begin{array}{c} 31.53 \pm \\ 10.14 \end{array}$	Pulsed Nd:YAG laser	NA	Λ = 1064, ED = 0.510–1.78, 10–40 Hz, PD = 0.12–0.15, S = 4.47	HIRO3 machine, ASA Laser company, Italy	VAS	GOOD
El-Hoshy [55]	2017	IPCS	PC	2	20	4/16	26.35 ± 9.85	AFCL	NA	stacking, 3; PD = 0.6; spacing, 200 μm PDL firstly: λ = 595, PD = 6-8,	SmartXide DOT [®] ; DEKA, Florence, Italy	VSS, POSAS	GOOD
Elrod [31]	2020	cohort (retro- spective)	PC	After the final laser session	17	8/9	11.37 ± 4.82	Combined AFCL + PDL (94%), with AFCL only (6%).	NA	PD = 0.45, S = 10, no more than 30% overlap; Secondly AFCL: 2–3% density, 250 Hz, 70–20 mJ per micropulse	PDL: V-beam2; Candela, Wayland, MA, USA; AFCL: DeepFX hand-piece (Ultrapulse, Lumenis)	VSS, POSAS	GOOD
El-Zawahry [51]	2015	NRCT	UAC	3	15	2/13	30.8 ± 11.3	AFCL	NA	30 W, 800 μ m spacing, 800 us dwelling time (the first session followed by 30 W, 300 μ m spacing, 800 us dwelling time) IPL: $\lambda = 530/560/580/630/755$	NA	VSS, P-POSAS, O-POSAS	FAIR
Elmelegy [56]	2018	IPCS	PC	1	65	49/16	49/16	E-light	NA	(differs from patients' skin color). ED = 6.25–6.47; S = 8–32. PD = 2–7, pulse delays 15–30 ms. RF: fluence = 10–12 J	Beijing Oriental Wison Mechanical & Electronic Co., Ltd.	VSS	GOOD
Gaida [52]	2004	NRCT	UAC	2	19	14/5	38 ± 13.97 (18–77)	LLLT	NA	$\lambda = 670, ED = 4$	Helbo [®] ; Gallspach, Austria	VSS	FAIR
Ge [32]	2022	Cohort (retro- spective)	PC	3	21	8/13	31.4 (15–47)	UFCL	NA	3–5% density, 30–300 Hz, 20–175 mJ, 1–60 W	Lumenis Ltd., Yokneam, Israel	Total POSAS	GOOD
Huang [57]	2021	IPCS	PC	6	12	7/5	32 ± 11	AFCL	Autologous fat injection in AFI group	8% density, 40~50 mJ/cm ² , 10–50 W	KL type fractional CO ₂ laser	mVSS	GOOD
Hultman [33]	2013	Cohort	PC	4.65	147	NA	26.9	PDL, UFCL, IPL, Alexandrite laser	NA	PDL: $\lambda = 595$, ED = 8.3 \pm 1.1 (5.0–10.0), PD = 1.5, S = 7; end point: ecchymosis; AFCL: 15% density, 600 Hz, 15 mJ/micropulse for deep penetration; 150 Hz and 70–90 mJ/micropulse for more superficial ablation; IPL: $\lambda = 515-590$, ED = 18–24; AL: $\lambda = 755$ with an aiming beam of $\lambda = 543$, S = 12, ED = 12.5	PDL:Candela V-beam, Wayland, MA, USA AFCL: Lumenis UltraPulse, ActiveFX, DeepFX handpieces, Santa Clara, CA, USA IPL/Nd: YAG/lightsheer diode Workstation, Santa Clara, CA, USA AL: Cynosure, Westford, MA, USA	VSS	GOOD

 Table 2. Baseline characteristics of patients in the trials included in the meta-analysis.

Author	Year	Study	Control	Follow-Up (Month)	Sample	Gender	Age	Treatment	Other Treatments	Parameter	Device	Outcomes	NIH
Tutio	reur	Design	conuor	after Final Treatment	Size	(M/F)	(Years)		Combined		Denie	Measure	
Issler-Fisher [45]	2021	Case-control	Conventional management	5.1	187	75/112	39 (IQR 27–49)	UFCL	NA	ActiveFxTM (3–45% Density, 250–300 Hz, 80–125 mJ), DeepFxTM (5–15% Density, 300 Hz, 15–50 mJ) SCAAR FxTM mode (1–5% Density, 250 Hz, 60–150 mJ)	Ultrapulse, Lumenis	VSS, O-POSAS, P-POSAS, ST	GOOD
Joo [53]	2022	NRCT	UAC	7 days after the 3rd laser treatment	14	14/0	$\begin{array}{c} 45.01 \pm \\ 15.03 \end{array}$	Er:YAG (non- ablative fractional laser)	NA	λ = 1550, 70 mJ (at level 7, with eight passes)	Fraxel Restore; Solta Medical, Pleasanton, CA, USA	ST	FAIR
Kemp Bohan [58]	2021	IPCS	PC	2	21	17/4	30.0 (24.5–40.5)	UFCL	NA	15% density, 300 Hz, 15 or 17.5 mJ	Lumenis UltraPulse Ltd., Yokneam, Israel	ST	GOOD
Khandelwa [34]	2014	Cohort (retro- spective)	PC	7	40	22/18	18 (1–70)	UFCL	NA	DeepFX [™] : 12.5–27.5 mJ, density of 15%. ActiveFX [™] : 90–125 mJ, density 3–5%.	Lumenis UltraPulse [®] , Santa Clara, CA	VSS	GOOD
Khedr [59]	2020	IPCS	РС	3	50	27/23	16.76 ± 7.72	Nd:YAG laser $(n = 25)$ or E-light (IPL + radiofre- quency) (n = 25)	NA	Nd: YAG: $\lambda = 1064$, ED = 45–75, PD = 25–45, S = 6. E-light:IPL: $\lambda = 530-755$, ED = 30–40, PD = 2–7 with 15–30 ms pulse delay, 8 mm × 32 mm hand piece. RF: 6–10 J/cm ³	Nd: YAG laser (Cynergy; Cynosure Inc, Westford, MA), E-light (two-handle beauty machine; Beijing Oriental Wison Mechanical & Electronic Co., Ltd.)	VSS	GOOD
Kono [54]	2005	NRCT	UAC	1	15	8/7	13.7 (1–42)	Long-pulsed PDL	NA	$\Lambda = 595, S = 7, ED = 9-10,$ PD = 1.5-10	model V-beam; Candela Laser Corporation, Wayland, MA	mVGH	FAIR
Lei [60]	2015	IPCS	PC	3.75	63	25/38	16–45	UFCL	Traditional Chinese medicine	P = 25~32 W, PD = 4~6, spacing 0.6~1.0 mm (for early stage of scar growth, 1.0 mm, decreasing with the number of treatments)	LJL35-CS Ultra Pulse CO ₂ Fractional Laser	VSS	GOOD
Li [35]	2021	Cohort (retro- spective)	PC	1	165	79/86	3.5 ± 3.02	UCFL	NA	5% density, 30–50 mJ/microbeam exposure	Lumenis Ltd., Yokneam, Israel	VSS, ST	GOOD
Li * [43]	2021	Case-control (retrospec- tive)	РС	12	105	46/59	39.5 ± 6.02	595 nm PDL	NA	PD = 0.45, ED = 5–9 (low ED: 5–7 and high ED = 7–9), S = 7	Vbeam Perfecta, Candela, USA	VSS, ST	GOOD

Follow-Up Study Gender Age Other Sample Outcomes (Month) NIH Author Year Control Treatment Parameter Device Treatments after Final Size Measure Design (M/F) (Years) Combined Treatment PDL: $\lambda = 595$, S = 7, PD = 0.45~1.50, PDL: Vbeam Perfecta, ED = $5.0 \sim 7.0$. CO₂: For scar height Candela, USA; CO₂: 595-PDL or <2 mm, choose Deep FX mode Ultra Pulse CO₂ Cohort (retro-Li [36] 2018 PC 1-2 221 81/140 $3-48(29 \pm 8)$ NA VSS, VAS GOOD UFCL (5~10% density, 25~50 mJ); for scar Fractional Laser spective) (Cornmedical Medical height ≥ 2 mm, choose Scaar FX mode (3~5% density, 60~120 mJ) Laser, Inc., USA) Case-control Conventional 3–5% density, 20–150 MJ, depth: UltraPulse[®] Encore; 1 - 1.5P-POSAS Liu [44] 2022 (retrospec-46 28/18 38.22 ± 10.28 UFCL NA GOOD surgery 0.4–4 mm LumenisTM tive) IPCS eCO₂ Laser; Lutronics Topical corti-2018 PC 3 10 3/7 9.7 (5-12) AFCL 8.4% density, 90-150 mJ at 30 W Corp., Seoul, South VSS GOOD Majid [61] (open-label costeroids study) Korea PDL: Syneron Candela PDL PDL: $\lambda = 595$, ED = 6.86 (5–10); VBeam Perfecta, VSS, Matuszczak 2021 IPCS PC 1.25 - 1.525 16/9 6.40 ± 1.72 followed NA GOOD P-POSAS AFCL: 75.12 mJ (54-80 mJ). Wayland, MA; AFCL: [62] by AFCL Smaxe 5-10% density, 30-50 mJ, depth Lumenis Ltd., Yokneam, P-POSAS, Miletta [63] 2021 IPCS PC 6 22 15/7 28 ± 16.8 UFCL NA GOOD 1.2–2.2 mm Israel O-POSAS, ST First pass: SCAAR FX (majority): for scar depth: 1–3 mm: 1.7% density. O-POSAS, 250 Hz, 101.6 mJ. Second pass: After all laser 49 Patel [37] 2019 Cohort PC 26/23 4.86 ± 4.5 UFCL NA Ultrapulse, Lumenis P-POSAS. GOOD DeepFX for scar depth less than 1 treatment total POSAS mm: 5.3% density, 266.2 Hz, 13.7 mJ and ActiveFX (minority) First: ScaarFX, shape 2, size 10, pulse 1, density 1%, repeat delay 0.3 s, 250 Hz, 70-120 mJ; Second: ActiveFX: 9% VSS, Poetschke density, 40 mJ, 350 Hz, pattern 1, size 2017 IPCS PC 6 10 3/7 39.3 ± 15.3 UFCL NA Ultrapulse, Lumenis O-POSAS. GOOD [64] 2, repeat delay 0.1 s. Finally: P-POSAS ActiveFX: 2% density, 100 mJ, 125 Hz, pattern 1, size 6, repeat delay 0.1 s Deep mode: 5-10% density, 15-30 MJ, depth of 550-800 µm. Superficial Cohort (retro-AcuPulse; Lumenis Ltd., Tan [38] 2021 PC 1 221 118/103 33.6 ± 11.8 AFCL NA VSS GOOD mode: 40% density, 70-150 MJ, depth spective) Yokneam, Israel of 50-150 µm

Author	Year	Study	Control	Follow-Up (Month)	Sample	Gender	Age	Treatment	Other Treatments	Parameter	Device	Outcomes	NIH
Tutioi	icui	Design	Control	after Final Treatment	Size	(M/F)	(Years)		Combined		Dente	Measure	
Tawfic [65]	2020	IPCS	PC	3	25	2/23	22.04 ± 9.92	AFCL OR FMR (fractional micronee- dle radiofre- quency)	NA	FMR: power level of eight to nine (max 70 w), an exposure time of 800 ms, a depth of 2 mm (using non-insulated needles, 2 Hz frequency, and 2 passes and diameters of 0.3 mm per needle). AFCL: 18–20 W, 800–1000 μs dwell time, 500–600 μm spacing (13% density), microspot size 120 μm, two to three stacks	FMR:VIVACE™ combine microneedling with bipolar RF; AFCL: DEKA Smartxide DOT, Italy	VSS, POSAS	GOOD
Tawfic [47]	2022	RCT	PC	1	20	2/18	24.80 ± 9.87 (16-48)	AFCL	NA	20 W, 800–1000 ms dwell time, and 2–3 stacks for scar thickness (low-density, 900 mm, medium-density, 600 mm, spacing (12.6% density), high-density, 300 mm spacing (25.6% density))	The DEKA; Smart Xide DOT, Calenzano, Italy	O-POSAS, P-POSAS	GOOD
Travis [39]	2022	Cohort	PC	1–2 weeks	23	16/13	49.1 (IQR: 36.7–58.6)	AFCL	NA	Firstly, SCAARFx modality 1% density, 70 mJ	Ultrapulse, Lumenis, Yokneam, Israel	VSS, O-POSAS, P-POSAS, total POSAS	GOOD
Wang [66]	2017	IPCS	PC	6	95	40/55	22.9 (12–55)	FMR (fractional mi- croplasma radiofre- quency)	NA	Roller tip at 50–80 watts; 3–4 passes in different directions over each area with a high rolling speed of 5 cm/s and a delay of 5–10 s between passes	Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel	O-POSAS, P-POSAS, total POSAS	GOOD
Weshahy [67]	2020	IPCS	PC	2	15	8/7	38.95 ± 8.85	AFCL	Combined with growth factors in group AFCL + GF	Smart stack, dot mode, power: 30 W, dwell time: 800 ms, spacing: 400 μ m and smart stacking: 2, depth 200 μ m, S = 15, 17% density. Readymade GFs after sessions for at least 6 h	SmartXide DOT [®] ; DEKA, Florence, Italy	VSS, O-POSAS, P-POSAS, total POSAS	GOOD
Woods [40]	2022	Cohort	PC	18 months after injury	21	NA	NA	PDL (13) or Nd:YAG Q-switched KTP laser (8) or combined	NA	PDL: λ = 595, S = 7–10, PD = 0.5–10, ED = 7–12, KTP: λ = 532, S = 2–6, ED = 1–6	V-Beam 595 pulsed dye laser (Candela), Nd: YAG Q-switched KTP laser (Cynosure)	Total POSAS	GOOD
Xie [41]	2018	Cohort	PC	11	221	118/103	8 (IQR: 4, 31)	PDL + AFCL	NA	PDL: λ = 595, S = 7–12, PD = 1.5–3.0, ED = 8.0~9.5. AFCL: For scar height <1 mm, choose Deep FX mode: 5~10% density, 25~50 mJ; for scar height ≥1 mm, choose Scaar FX mode: 3~5% density, 80~150 mJ	PDL, Vbeam Platinum, Candela, USA AFCL: UltraPulse Encor, Lumenis, USA	Self-made scar rating score (refer to the VSS), ST	GOOD

		Study		Follow-Up (Month)	Sample	Gender	Age		Other			Outcomes	
Author	Year	Design	Control	after Final Treatment	Size	(M/F)	(Years)	Treatment	Treatments Combined	Parameter	Device	Measure	NIH
Yang [68]	2022	IPCS	PC	1	169	92/77	3.28 (1–6)	UFCL	NA	 Scar height ≤2 mm, ActiveFX: 125 mJ, 50 Hz; Deepn FX: 25–50 mJ, 5–10% density Scar height ≥2 mm, ActiveFX: 150 mJ, 150 Hz; Deepn FX: 60–120 mJ, 3–5% density 	UltraPulse Encor, Lumenis, Santa Clara, CA, USA	VSS	GOOD
Yang [46]	2021	RCT	PC	3	20	13/7	26 (3–67)	PDL	NA	$\lambda = 595, S = 7, ED = 5-7$ PD = 0.45-1.50	America, Candela Company	VSS	GOOD
Zuccaro [42]	2021	Cohort	PC	12	32	13/7	5.89	AFCL or AFCL + PDL	NA	PDL: $\lambda = 595$, ED = 5.50 (5.00–7.00); PD = 0.45 (0.45–1.50) AFCL: deep: 5% density; 70.00 mJ	PDL (Vbeam Perfecta, Candela Corporation, Wayland, MA, USA) AFCL (CO ₂ RE, Candela Corporation, Wayland, MA, USA)	VSS, P–POSAS, O–POSAS	GOOD
Zuccaro [69]	2018	IPCS	PC	Differed for each patient	71	NA	6.62	PDL or AFCL or AFCL + PDL	NA	Fusion: core energy: 70.00 mJ, ring energy: 48.00–55.20 mJ, 20–25% density PDL:ED = 6.45 (5–9). AFCL: core energy 70.86 mJ (53–78 mJ); settings: fusion and deep modes (most-used)	PDL: Syneron Candela Vbeam Perfecta, Wayland, MA, USA AFCL:Syneron Candela CO ₂ RE, Wayland, MA, USA	VSS	GOOD

Randomized controlled trial (RCT); non-randomized controlled trial (NRCT); in-patient controlled study (IPCS); untreated area control (UAC); pretreatment control (PC); Vancouver Scar Scale (VSS); Patient and Observer Scar Assessment Scale (POSAS); visual analogue scale (VAS); scar thickness by ultrasonography (ST); modified Vancouver General Hospital (mVGH); ultrapulse fractional CO₂ laser (UFCL); ablative fractional CO₂ laser (AFCL); pulsed dye laser (PDL); low-level laser treatment (LLLT); intense pulsed light (IPL); IPL + radiofrequency (E-light); fractional microneedle radiofrequency (FMR); wavelength (nm) (λ); pulse duration (PD, in ms); energy density (J/cm²)(ED); spot size (mm) (S); not available (NA).* In order to distinguish between the two Li's articles published in 2021, we have marked this one with an asterisk [43].

3.2. Time of Intervention

Photo-electric therapy offered significant improvement for each period of burn scarring (Figure 2) (Chi² = 6.05, df = 2 (p = 0.05), I² = 67.0%). Furthermore, for the group with scarring for over one year and the group with scarring between six months and one year, there was a significant difference in improvement (Chi² = 5.43, df = 1 (p = 0.02), I² = 81.6%) (Figure S1). However, there was no significant difference between the group with less than 6 months of scarring compared to the other two groups. For deeper insight, we also analyzed the improvement using only thickness and VSS. Interestingly, we found that in terms of thickness, the photo-electric therapy presented a significant difference in improvement of the scar over one year (Figure 3) (Chi² = 6.40, df = 2 (p = 0.04), I² = 68.8%). However, in VSS, although there was no significant difference between the two groups, scarring less than one year presented a higher effect size than scarring over one year (Figure 4) (Chi² = 1.37, df = 2 (p = 0.50), I² = 0%).

16.1 Oper typer 0 3.4 / 12.7 / 12 33.33 10.7 / 10.8 / 0.4 / 1 EHeady V017 5.16 1.12 20 7.7 / 20 1.7 / 10.8 / 0.4 / 1 EHeady V017 5.16 1.12 20 7.7 / 20 1.7 / 10.8 / 0.4 / 1 ELZwarky 2015 Keloid 1.7 / 11.4 3 1.3 / 20 3.1 / 8 -0.03 / 12.5 / 2.0 / 7 ELZwarky 2015 Keloid 1.7 / 20 1.4 / 3 1.3 / 2.0 / 1.7 / 11.8 / 2.1 / 10.0 / 3.2 / 17.1 / 11.8 / 2.2 / 7.1 / 13.8 / 2.4 / 12.7 / 2.1 / 11.1 / 10.8 / 2.2 / 14.2 / 2.2 / 10.0 / 10.8 / 0.0 / 10.9 / 10.8 / 0.0 / 10.0 / 10.8 / 0.0 / 10.0 / 10.8 / 0.0 / 10.0 / 10.8 / 0.0 / 0.0 / 10.1 / 0.0 / 0.0 / 0.0 / 10.1 / 0.0 / 0.	Study or Subgroup	Expe Mean	eriment SD	al Total	C Mean	ontrol SD	Total	Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl		
Ehelony 2017 518 517 46 118 20 776 207 20 17% 152 21.079 44 252 21.079 44 252 21.079 44 252 21.079 44 252 21.071 74 44 21.05 21.054 452 21.071 74 44 21.05 21.054 452 21.071 74 451 442 50.042 452 21.071 74 451 442 50.042 452 21.071 74 451 442 50.042 452 21.071 74 451 442 50.042 452 21.071 74 451 442 50.042 452 21.071 74 451 442 50.042 452 21.071 74 451 442 50.042 452 21.072 174 451 442 50.042 452 21.072 174 451 442 50.042 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 21.071 74 158 452 201 758 452 11.071 158 452 21.021 77 72 55 22.01 20 158 51 158 422 11.021 74 158 452 20 100 168 452 100 168 452 201 74 158 220 77 163 22 152 20 121 524 20 108 41.023 100 168 41.021 74 121 52 150 52 100 178 41.021 74 121 52 150 52 11.071 443 142 21.020 174 451 142 120 21 220 772 1425 240 20 121 524 20 108 41.023 100 168 41.020 174 41.020 174 11.050 17												
Eind 2020 488 173 17 765 212 71 17% - 1.40 215.0-04	Douglas 2019	31.47	12.75	19	33.53	10.74	19	1.8%	-0.17 [-0.81, 0.47]	+		
E-2.wahry 2015 HPTP 9 9 56 9 9 3 8 16% 000 [0.00 0.09] E-2.wahry 2015 HPTP 14 3 15.2 11 3 14 6 00 81 12.2 201 4.4 12 3 014 0 14 1 5 15% 0.00 [0.00 0.09] 4.4 12 3 014 0 14 1 5 15% 0.00 [0.00 0.09] 4.4 12 1 40 7.6 12.1 40 12% 0.25 [0.00 19] 4.5 128 140 7.6 12.1 40 12% 0.25 [0.00 19] 4.5 128 140 7.6 12.1 40 12% 0.25 [0.00 19] 4.5 128 140 7.6 12.1 40 12% 0.25 [0.00 19] 4.5 128 140 7.6 12.1 40 12% 0.25 [0.00 19] 4.5 128 140 7.6 12.1 40 12% 0.25 [0.00 19] 4.5 128 140 7.6 12.1 40 12% 0.25 [0.00 19] 4.5 128 140 7.6 12.1 40 12% 0.25 [0.00 19] 4.5 128 12.1 42 11 12% 0.21 [0.00 10] 4.5 128 12.1 42 11 12% 0.21 [0.00 10] 4.5 128 12.1 42 11 12% 0.21 [0.00 10] 4.5 128 12.1 42 [0.0 10] 4.5 128 12.1 41 [0.0 10] 4.5 128 12.1 41 [0.0 10] 4.5 128 12.1 42 [0.0 10] 4.5 128 12.2 4.1 42 [0.0 10] 4.5 128 12.1 42 [0.0 10] 4.5 128 12.2 4.1 42	El-Hoshy 2017	5.18	1.18	20	7.76	2.07	20	1.7%	-1.50 [-2.21, -0.79]			
E-Zwaho 2015 Kolou 6-Zwaho 2 (27) 2015 Kolou 7-Zwaho 2 (27) 2015 Kolou 7	Elrod 2020	4.88	1.73	17	7.65	2.12	17	1.7%	-1.40 [-2.16, -0.64]	-		
E-Zwaho 2015 Kolou 6-Zwaho 2 (27) 2015 Kolou 7-Zwaho 2 (27) 2015 Kolou 7	El-Zawahry 2015 HPTP	9	5.6	8	9	3	8	1.6%	0.00 (-0.98, 0.98)	+		
Gelds > 12/2 2004 -0.241 142 5 1.5% -0.21/17/1.12 Disperting 2011 0.51 121 147 0.27 147 147 147 Disperting 2011 0.51 121 167 0.27 147 158 -2.241/27, 1.12 - Mich 2011 0.51 121 167 0.27 147 158 -2.241/27, 1.12 - Mich 2011 0.51 123 148 0.21 0.18 -0.210/16, 0.19 - Mich 2011 0.52 0.53 0.25 0.28		17.5		3	13.5	2.1	3					
Hahman 2013 Hahman 2013 Hahma	Gaida > 12m 2004	-0.344	1 4 2	5	-0.149	1.41	5	1.5%		+		
Issler-Finder 201 Issler-Finder		5.16	1.92	147		2.37	147			-		
Spance wait 2014 Spance wait												
Kono 2005 3 26 134 15 68 004 15 16% 272 528 239 17 11 15 68 004 15 16% 272 528 239 17 14 14 11 98 004 16% 238 539 17 14 14 11 98 004 16% 238 539 17 14 14 15 06% 238 539 17 14 14 15 06% 238 539 17 15 00 16% 238 539 17 15 00 16% 238 539 17 15 00 16% 124 227 028 15% 004 124 227 028 15% 004 124 227 028 15% 004 124 227 028 15% 004 124 227 028 15% 004 124 227 028 15% 004 124 227 028 15% 004 124 227 028 15% 004 124 227 028 15% 004 124 24 124 15% 004 148 005 009 16% 004 124 24 124 15% 004 148 005 009 16% 004 124 24 124 15% 004 148 005 009 16% 004 124 124 124 15% 004 148 005 009 16% 004 124 124 124 15% 004 148 005 009 16% 004 124 124 124 15% 004 148 005 009 16% 004 124 124 124 15% 004 148 005 009 16% 004 124 124 124 124 15% 004 148 005 009 16% 004 124 124 124 124 15% 004 148 005 009 16% 004 124 124 124 124 124 15% 004 148 005 009 16% 004 124 124 124 124 124 124 124 124 124 12										_		
Li > 127 127 221* 4.3 1.4.4 11 82 1.7.7 11 1.9.8 33 14.6.7.1.9 4 Midia 201 0.96 0.33 22 1.5 0.6 22 1.9.8 0.951.55.0.33 4 												
Majid 2018 2 2 28 10 7 1 6 10 16% - 23 8 3 28 17, Pakel 2019 6 919 148 4 8 857 175 49 18% - 05 15 8, 0.33 1 - Pakel 2019 6 919 148 4 8 857 175 49 18% - 05 15 8, 0.33 1 - Pakel 2017 1 37 28 5 10 2 20 10 5 44 10 18% - 124 15 8, 0.31 - Tomole APCL 2022 14 25 28 02 20 1 5 24 10 18% - 138 12 07, 0.68 - Tomole APCL 2022 14 25 28 02 22 5 74 135 25 16% - 448 15 55, 3.31 - Tomole APCL 2022 14 25 3 20 20 1 5 24 15 25 16% - 448 15 55, 3.31 - Tomole APCL 2022 14 25 15 20 20 21 5 34 15 2 5 16% - 448 15 55, 3.41 - Tomole APCL 2022 17 5 5 27 15 36 46 91 5 17% - 338 14 23, 74 10 - Tomole APCL 2022 17 5 5 27 15 36 46 91 5 14% - 458 16 01, 3.14 - Tomole APCL 2022 17 5 5 27 15 36 46 91 5 14% - 458 16 01, 3.14 - Tomole APCL 202 17 5 2 74 15 36 46 91 5 14% - 458 16 01, 3.14 - Tomole APCL 202 17 5 2 74 15 36 46 91 5 14% - 458 16 01, 3.14 - Tomole APCL 202 17 5 2 74 15 36 46 91 5 14% - 458 16 01, 3.14 - Tomole APCL 202 17 5 2 74 15 36 46 91 5 14% - 458 16 01, 3.14 - Tomole APCL 202 20 17 5 2 74 16 28 0 - 000001) + 20% - Stational Effect Z = 7.70 (P - 000001) + 208 46 11 2 4 34 1 18% - 0.071 (15 4, 0.08, 0.01 + Tomole APCL 202 20 17 5 2 14 4 - 0.094 182 14 17% - 0.771 (15 4, 0.08, 0.01 + Tomole APCL 20 7 7 8 05 12 18 0 0 12 0 89 - 48 61 (27 7, 9.69 + Stational Effect Z = 7.70 (P - 000001) + 208 48 172 9, 380 + Testor oracle Hetric Z = 7.70 (P - 000001) + 208 48 179 3 80 112 4 30 18% - 1.051 (13 4, 0.02 + Tomole APCL 20 1 74 5 10 2 2 11 12 5 10 1 18% - 0.771 (15 4, 0.02 + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle Hetric Z = 7.70 (P - 000001) + Testor oracle												
Mietha 2021 005 0.33 22 1.35 0.48 22 1.85 0.05 1.58 0.33												
Paiel 2019 6 0.19 14.9 40 0.57 17.5 49 18% -124 (16.8, 0.51) - Paiel 2019 7.7 2 5 9.2 1.9 65 19% -0.78 (1.2, 1.2, 1.2, 1.2, 1.2, 1.2, 1.2, 1.2,									-2.30 [-3.30, -1.17]	_		
Poletscher 2017 13.3 2.060 10 2.36 109 10 16% -1.24 [221, 2.28] Tamole APCL 2022 14.25 2.69 20 201 5.24 20 18% -0.78 [1.7, 0.39] Tamole APCL 2022 14.25 2.60 20 201 5.24 20 18% -1.38 [2.20, 0.68] Tamole Mich end Mix 2020 2.56 0.32 2.57 5.41 3.5 2.5 1.6% -4.48 [5.55, 3.41] Tamole Mich end Mix 2020 2.7 7.22 2.65 3.3 20 5.7 4.2 20 5.8 20 1.7 4.57 5.4 2.55 1.4 1.4 2.20 0.68] Tamole Mich end Mix 2020 2.7 7.22 2.65 3.3 20 5.5 1.6% -0.54 [1.152, 0.06] Tamole Mich end Mix 2020 2.7 7.22 2.55 5.3 20 5.5 1.6% -0.54 [1.152, 0.06] Tamole Mix 2020 2.7 7.22 2.7 15 3.8 4.69 15 1.4% -0.54 [1.152, 0.06] Tamole Mix 2020 2.7 7.2 2.7 15 3.8 4.69 15 1.4% -0.54 [1.152, 0.06] Tamole Mix 2020 2.7 7.2 2.7 15 3.8 4.69 15 1.4% -0.55 [1.55 4.35 [5.54, 2.56] Weshalvy APCL -0.10 2.0 2.7 7.6 2.0 2.0 00001); P= 90%, Tation consult Mix 2.0 20, 0.1 Pice X.28 0.0 4 2.6 Pice 0.00001); P= 90%, Tation consult Mix 2.0 20, 0.1 Pice X.28 0.0 4 2.6 Pice 0.00001); P= 90%, Tation consult Mix 2.0 20, 0.1 Pice X.28 0.0 4 2.6 Pice 0.00001); P= 90%, Tation consult Mix 2.0 20, 0.1 Pice X.28 0.0 4 2.6 Pice 0.00001); P= 90%, Tation consult Mix 2.0 20, 0.1 Pice X.28 0.0 4 2.6 Pice 0.00001); P= 90%, Tation consult Mix 2.0 20, 0.1 Pice X.28 0.0 4 2.6 Pice 0.00001); P= 90%, Tation consult Mix 2.0 20, 0.1 Pice X.28 0.0 4 2.6 Pice 0.00001); P= 90%, Tation consult Mix 2.0 20, 0.1 Pice X.28 0.0 4 1.2 0.0 2.0 2.0 4 4.0 2.0 0.0 1.0 4.0 4.0 0.0 2.0 1.0 4.0 4.0 0.0 0.0 1.0 4.0 4.0 0.0 0.0 1.0 4.0 4.0 0.0 0.0 0.0 0.0 1.0 4.0 4.0 0.0 0.0 0.0 1.0 4.0 4.0 0.0 0.0 0.0 1.0 4.0 4.0 0.0 0.0 1.0 4.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0									-0.35 [-1.56, -0.55]	a second		
Ta > 12m >												
Tavic APCL 2022 14 25 269 20 201 524 20 18% - 139 2207.069												
Tardie Find 2022 1465 35 20 223 553 20 17% -156 [230.066] Tardie Ling density 2020 396 14.3 25 7.64 1.35 25 17% -32.01 337, 1341 Tardie main density 2020 396 14.3 25 7.64 1.35 25 17% -2.001 337, 1341 Trained result are strained by 2020 17.5 25 17 23 856 155 23 18% -0.64 [13, 0.05] Trained result are strained by 2020 17.5 25 17 23 856 155 23 18% -0.64 [13, 0.05] Trained result are strained by 2020 17.5 25 17 55 2.5 17% -3.35 (1.84, -2.56) Trained result are strained by 2020 17.5 28.56 (1.26, 2												
Tawfe try density 2020 2.66 0.02 25 7.64 1.35 25 1.75 4.44 [5.65,3.41] Tawfe tow density 2020 3.16 1.28 25 7.64 1.35 25 1.75 4.30 (3.01.337,1.54) Tawfe tow density 2020 3.16 1.28 25 7.64 1.35 25 1.75 4.30 (3.01.337,1.54) Tawfe tow density 2020 3.16 1.28 25 7.64 1.35 25 1.75 4.30 (3.01.337,1.54) Weinhary AFCL on 2020 7.14 2.57 3.0 65 5.14 (5.28 0.5 1.88 4.02.44) Weinhary AFCL on 2020 7.1 2.9 2.73 1.5 3.64 6.69 1.5 1.58 4.36 1.51,3.14 Weinhary AFCL on 2020 7.1 2.9 1.1 2.81 15 3.69 5.46 15 1.58 4.36 16.31,3.14 Weinhary AFCL on 2020 7.1 2.9 1.1 2.81 15 3.69 5.46 15 1.58 4.38 15.13,4.41 15 Subtoal (19% C) 5 2.7 1.1 2.81 15 3.69 5.46 15 1.58 4.35 1.51,1.54, 1.15] Weinhary AFCL on 2020 7.1 6.5 2.1 14 -0.094 1.82 14 1.7% -0.77 [1.54,0.00] Huang AFCL +7202 7.70 (P < 0.00001) Huang AFCL +7202 7.70 (P < 0.00001)												
Tardie tow density 2020 3 99 14 3 25 764 135 25 17% -260 1337 1.84 Tradie radiu density 2020 17 46 35 5 39 65 24 152 95 17% -260 1337 1.84 Tradie radiu density 2020 17 45 27 23 65 81 65 23 16% -0.64 [+13,065] Weshark AFC L +0F 2020 17.95 2.73 15 38 669 15 14% -4.56 [+0,13.14] Weshark AFC L +0F 2020 17.95 2.73 15 38 669 15 14% -4.56 [+0,13.14] Weshark AFC L +0F 2020 17.95 2.73 15 38 669 15 15 4% -4.56 [+0,13.14] Weshark AFC L +0F 2020 17.9 5 2.3 16 61 24 4 17% -0.77 [+154,0.00] Heard Order 2 -0.0 (.01+2.78 86.0) d= 26 (+0.0001), P= 99% Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 7.70 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 7.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 5.80 (P < 0.00001) Test for overall effect Z = 7.80 (P < 0.00001) Test for										—		
Tawle medium density 202 3:16 1:28 25 7.64 1:35 25 1.7% -3.35 [4:32, -2.47] Tawle 202 7.42 257 23 659 1:55 23 18% -0.64 [+13, 0.05] Weinshy AFCL on 2020 7:19 2:05 2.73 15 86 649 15 1:5% -3.35 [5:32, -2.60] Weinshy AFCL on 2020 7:19 2:05 2.73 15 86 649 15 1:5% -3.35 [5:32, -2.60] Weinshy AFCL on 2020 7:19 2:05 2.73 15 86 649 15 1:5% -3.35 [5:32, -2.60] Weinshy AFCL on 2020 7:19 2:05 2:05 2:05 2:05 2:05 2:05 2:05 2:05												
Travis 2022 7, 42 257 23 8.58 1.55 23 1.8% -0.54 1.13, 0.05 Weshalty AFCL + 0F 2020 17.95 2.73 15 38 4.69 15 1.5% -0.72 [H 52, 0.90] Weshalty AFCL + 0F 2020 17.95 2.73 15 38 4.69 15 1.5% -0.58 [5 2.5 2.66] Weshalty AFCL + 0F 2020 17.95 2.73 15 38 4.69 15 1.5% -0.59 [5 2.5 2.66] Weshalty AFCL + 0F 2020 18 2.8 4.61 2.4 4 1.8% -1.04 [H 68-0.39] Staticatio 2127 2018 2 14 4 0.09 (H = 28 (P < 0.00001), P = 905K Test for overall effect Z = 7.70 (P < 0.00001), P = 905K Test for overall effect Z = 7.70 (P < 0.00001), P = 905K Hang AFCL + 4F1 2021 4.5 0.4 12 138 0.6 12 0.8% -9.077 [H 54, 0.00 Hang AFCL + 4F1 2021 4.5 0.4 12 138 0.6 12 0.8% -9.077 [H 54, 0.01 J = 20 2022 0 0.41 80 0.5 0.99 0.81 8.9% -0.077 [H 54, 0.01 J = 20 2022 0 0.41 80 0.5 0.99 0.81 8.9% -0.077 [H 54, 0.01 J = 20 2022 0 0.41 80 0.5 0.99 0.81 8.9% -0.077 [H 54, 0.01 J = 20 2022 0 0.41 80 0.5 0.99 0.81 8.9% -0.077 [H 52, 0.56] Hang AFCL + 4F1 2021 4.1 4.09 4 182 14 17% -0.077 [H 54, 0.01 J = 20 2022 0 0.41 80 0.5 0.99 0.81 8.9% -0.076 [H 53, 7.74, 0.18] Kerp Bohan 2021 7.17 202 4 2.92 5 181 31 8% -0.79 [H 32, 0.21 J = 20 2021 7.17 202 4 2.92 5 182 1.33 2.5 15% -0.61 P 7.57, 4.01 Hang AFCL + 467 [2021 14.25 6.98 0.92 1.83 1.8% -0.71 [H 32, 0.52] Hang AFCL + 467 [2021 7.77 2.02 4 0.92 2.18 0.51 2.93 1.83 1.88 -0.17 [H 32, 0.52] Hang AFCL + 467 [2021 7.77 1.20 14 9.25 1.8% -0.13 [H 085, 0.59] Hater 20 2021 7.17 1.07 2.23 4.8 0.9 2.1 8.6 1.98 4.77 [H 3.98 1.99] Lo = 3m 2021 7.17 1.07 2.23 4.3 0.8 1.9 2.18 (H 19.27 5.20] Hater 20 20 20 3.86 1.90 2.23 1.8 15 1.7% -0.13 [H 085, 0.59] Hater 20 20 20 20 3.86 1.10 2.18 2.18 1.18 3.17 1.7% -0.13 [H 085, 0.59] Hater 20 20 20 20 2.2 2.6 1.98 2.18 2.11 1.95 1.92 1.11 -0.21 J = 25 1.92 (H 11.93 1.92 1.92 1.18 3.19 1.77 1.92 4.13 3.17 1.7% -0.73 [H 085, 0.59] Hater 20 20 20 2.2 2.1 1.92 1.22 1.12 5 1.8% -0.74 [H 0.94 1.92 2.91 [H 19.18 1.90 1.7% -0.73 [H 0.85, 0.59] J = 3m 20 201 2.5 2.27 1.5 2.92 2.20 1.9% 4.73 2.17 4.73 1.9 1.9 1.9% 4.73 2.17 4.73 1.9 1.9% 4.73 2.17 4.73 1.9 1.9% 4.73 2.17	Tawfic low density 2020	3.96	1.43	25	7.64	1.35	25	1.7%	-2.60 [-3.37, -1.84]	—		
Vang 2017	Tawfic mediun density 2020	3.16	1.28	25	7.64	1.35	25	1.7%	-3.35 [-4.23, -2.47]			
Wang 2017 46.35 6.3 96 5.34 6.28 95 1.8% -121 152, 0.90 7 Weshark AFCL 6P 2020 176 2.07 175 36 6.69 15 1.4% -121 152, 0.90 7 Weshark AFCL 6P 2020 179 273 15 36 5.4 6.9 15 1.5% -3.95 5524, 2.66 9 Weshark AFCL 6P 2020 179 202 11 2.91 15 36.95 4.69 15 1.5% -3.95 5524, 2.66 9 Juncat 0.95% (0.10 cm ² - 26.86.0 df = 26.(P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001) Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 7.70 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P = 0.0% Test for varial effect Z = 5.00 (P - 0.00001), P	Travis 2022			23								
Weshark APCL + 0F 2020 17.95 27.2 15 38.4 64.9 15 1.4% -4.66.6.201, 31.4 Weshark APCL + 0F 2020 38.14 17.33 21 58.25 15 15% -39.5524, 26.6 Woods 2022 38.14 17.33 21 54.26 12.44 11.8% -1.04.F169.0.39 Statucal (5% C) 5 2.3 46.11 2.4 1.8% -1.04.F169.0.39 Statucal (5% C) 5 1.4 -0.8% -8.66.12.75,-6.56 -0.0001) Hearogenety, Tau" = 0.30, Ch" = 228.68, 0.41 = 26.7 0.04.1 1.82 14 1.7% -0.07F154,0.00 Huang APCL + AF2021 4.5 0.4 1.25 1.7 1.24 1.7% -0.07F1450,0.01 Huang APCL + AF2021 4.0 0.3 1.21 1.8% -0.07F1430,0.23 0.64 Job 2021 0.41 0.3 2.21 1.89 -0.07F142,0.104 0.64 Job 2021 0.66 1.25 2.82 1.18% -0.07F142,0.104 0.64 Job 2021 0.62 9.21 1.33 25 1.85%	Wang 2017	46.35	5.3	95	53.41	6.28	95	1.8%		-		
We shark AFCL only 2020 121 1 291 15 36 95 4 669 15 1 5% $-395 1524, 266$ Zuccaro 27 12n 2018 5 2 34 611 24 34 16% $-050 1098, -001-050 12n 2018 5 2 34 611 24 34 16% -050 1098, -001-050 12n 2018 5 2 34 611 24 34 16% -050 1098, -001-050 12n 2010 - 165 2 1 14 0 094 182 14 173 4 0.55 1434, 1.151-156 1 x 0 x and 16m C 2 7 .70 0 4 0 00001)-152 6 m 19-156 1 x 0 x and 16m C 2 7 .70 0 4 0 00001)-152 6 m 19-156 1 x 0 x and 16m C 2 7 .70 0 4 0 00001)-152 6 m 19-156 1 x 0 x and 16m C 2 7 .70 0 4 0 00001)-152 6 m 19-156 1 x 0 x and 16m C 2 7 .70 0 4 0 00001)-152 6 m 19-156 1 x 0 x and 16m C 2 7 .70 0 4 0 00001)-152 6 m 19-156 1 x 0 x and 16m C 2 7 .70 0 4 0 00001)-156 2 m 10 - 100 5 0 2 0 10 - 10 - 10 - 10 - 10 - 10 - 10 $												
Woods 2022 3814 17.33 21 64.28 12.84 21 18% -104[+69.039] Subclaid [9% C] 916 76 945.7% -1.55[-1.94, -1.15] Heterogeneity Tau" = 0.90, Ch" = 268.60, d= 2.6 ($e = 0.0001$), $e = 90\%$ Test for overall effect $Z = 7.70 (e = 0.00001)$ 16.2 6m·ly Gaida < 127 2004 -1.65 2.1 14 -0.094 182 14 1.7% -0.77[+1.54, 0.00] Huang ACCL ark 2021 7.8 0.6 12 138 0.6 12 0.9% -9.66[+12.7, 6.56] Huang ACCL ark 2021 7.8 0.6 12 138 0.6 12 0.9% -9.66[+12.7, 6.56] Huang ACCL ark 2021 0.041 0.8 0.05 0.99 88 1.9% -0.07[+1.54, 0.16] And 0.4 0.3 21 0.71 0.44 0.3 21 0.8% -9.66[+12.7, 6.56] Huang ACCL ark 2021 0.041 0.8 0.05 0.99 88 1.9% -0.07[+1.54, 0.16] And 0.4 0.3 21 0.71 0.44 0.3 21 0.8% -9.66[+12.7, 6.56] Huang ACCL ark 2021 0.041 0.8 0.5 0.99 88 1.9% -0.07[+1.52, 0.16] And 0.4 0.3 21 0.71 0.43 0.5 2.93 1.81 42 11.8% -0.07[+1.52, 0.16] Huang ACCL ark 2021 1.43 0.5 2.93 1.81 42 1.18% -0.07[+1.52, 0.62] Huang ACCL ark 2021 7.17 202 43 9.83 1.81 42 1.18% -1.07[+1.52, 0.62] Huang ACCL ark 2011 7.17 202 43 9.83 1.81 42 1.18% -1.07[+1.52, 0.62] Huang ACCL ark 2011 7.17 202 43 9.83 1.81 43 0.18% -0.97[+1.52, 0.62] Huang ACCL ark 2011 7.17 202 43 9.83 1.81 43 0.18% -0.97[+1.52, 0.62] Huang ACCL ark 2011 7.17 202 43 9.85 1.83 1.93 55 18.3% -0.013[+0.50, 0.59] Huang ACCL ark 2011 7.15 2.224 1.33 1.79 3.55 18.3% -0.013[+0.52, 0.23] Huang ACCL ark 2011 7.15 2.224 1.33 1.79 3.55 18.3% -0.013[+0.52, 0.23] Huang ACCL ark 2011 7.15 2.224 1.33 25 1.8% -0.047[+1.04, 0.10] Huang ACCL ark 2013 7.11 2.5 12.2 1.2 1.2 1.3 25 1.8% -0.047[+1.04, 0.10] Huang ACCL ark 2013 7.11 2.5 12.2 1.2 1.2 1.4 1.3 35 1.7% -0.13[+0.52, 0.59] Huang ACCL ark 2014 6.52 2.34 4.57 1.9 0.77 1.11, 0.32 1 - 1.04 0.10 0.17 1.10 0.10 1.00 0.17 1.10 0.13 1.10 1.10 0.12 1.10 0.10 0.10 0.10 0.10												
$ \begin{array}{c} Zuccaro > 12m 2018 & 5 & 2 & 34 & 6.11 & 2.4 & 34 & 18\% & -0.50 [0.98, -0.01] \\ Heterogeneity, Tat2+ = 0.90, Ch2+ = 268 B0, dr = 26 (P < 0.00001); P = 90\% \\ Test for overall effect Z = 7.70 (P < 0.00001) \\ \textbf{16.2 Gm} \cdot \textbf{V} \\ Gaida < 12m 2004 & -1.65 & 2.1 & 14 & -0.094 & 1.82 & 14 & 1.7\% & -0.77 [+1.54, 0.00] \\ Huang ACFL - 0.00001 & -1.65 & 2.1 & 14 & -0.094 & 1.82 & 14 & 1.7\% & -0.77 [+1.54, 0.00] \\ Huang ACFL - 0.00001 & -1.65 & 2.1 & 14 & -0.094 & 1.82 & 14 & 1.7\% & -0.77 [+1.54, 0.00] \\ Huang ACFL - 0.00001 & -1.65 & 2.1 & 14 & -0.094 & 1.82 & 14 & 1.7\% & -0.77 [+1.54, 0.01] \\ Huang ACFL - 0.00001 & -1.65 & 2.1 & 14 & -0.094 & 1.82 & 14 & 1.7\% & -0.77 [+1.54, 0.01] \\ Huang ACFL - 0.00001 & -0.18 & 0.05 & 0.99 & 81 & 16\% & -0.07 [+1.32, 0.23] \\ Kermg Bohan 2021 & 0.41 & 0.3 & 21 & 0.71 & 0.43 & 21 & 1.7\% & -0.07 [+1.32, 0.02] \\ Huang ACFL - 0.000 & 0.66 & 2.91 & 21 & 3.3 & 25 & 1.5\% & -0.07 [+1.32, 0.62] \\ Huang ACFL - 0.000 & -0.68 & 2.14 & 2.5 & 1.7\% & -0.19 [+3.7, 2.10] \\ L > 6m 2021 & 7.17 & 2.02 & 4.9 & 2.5 & 18.8 & -1.00 [+1.48, 0.51] \\ Haterogeneity, Tau2+ = 2.11, Chr2+ = 2.34$										_		
Subtoal (9% C) 9% C) 976 769 45.7% $1.55[1.94, 1.15]$ Test for overall effect Z = 7.70 (P < 0.0001), P = 90% Test for overall effect Z = 7.70 (P < 0.0001), P = 90% Test for overall effect Z = 7.70 (P < 0.0001), P = 90% Subtoal (9% C) 78 06 12 138 06 12 0.8% $-9.66[1.275, 6.56]$ Huang ACCL + AP12021 7.8 06 12 138 06 12 0.8% $-9.66[1.275, 6.56]$ Huang ACCL + AP12021 7.8 0.6 12 13.8 0.6 12 0.8% $-9.66[1.275, 6.56]$ Huang ACCL + AP12021 0.041 0.3 21 0.18% $-0.07[1.52, 2.010]$ -0.02022 0.0 0.41 0.8 0.09 0.98 0.8 1.8% $-0.07[1.52, 2.010]-0.02022 0.0 0.86 2.9 12 1.33 25 1.5% -619[7.57, 4.81]Neder N2020 2.08 0.86 2.9 12 1.33 25 1.5% -619[7.57, 4.81]-0.0211 7.17 2.02 43 9.25 1.81 43 1.8% -1.07[1.53, 0.62]-0.0211 7.17 2.02 43 9.25 1.81 43 1.8% -1.07[1.53, 0.62]-0.0211 7.17 2.02 43 9.25 1.81 43 1.8% -1.07[1.53, 0.62]-0.0211 7.17 2.02 43 9.25 1.81 43 1.8% -1.07[1.53, 0.62]-0.0211 7.17 2.02 43 9.25 1.81 43 1.8% -1.07[1.53, 0.62]-0.0211 7.17 2.02 43 9.25 1.81 39 1.83 1.09 0.01]-0.0211 7.17 2.02 43 9.25 1.83 9.04 1.83 0.04 1.10 - 0.00001)Table 2.020 16 52 2.34 3.8 8.8 1.9 34 1.8% -0.47[1.04, 0.51]-0.0211 7.11 1.8 2.05 2.44 0.22 1.91 25 1.8% -0.47[1.04, 0.10]-0.0211 7.11 1.8 0.57 15 -0.09 0.76 15 1.7% -0.03[1.08, 0.59]Heterogeneity Tau2 = 2.11, 0.04 = 2.34.3, def 1.10 P < 0.00001)Table 2.000 55 01 8.119 2.1 7.00 3 7.14 21 1.8% -0.47[1.10, 0.21]-0.0211 6.55 2.23 1.25 1.22 11 25 1.8% -0.47[1.10, 0.2]-0.0211 6.55 2.23 2.28 69 3.80 1.56 1.98 -0.07[1.10, 0.2]-0.0211 6.55 2.23 2.28 69 3.80 1.56 1.93 -0.07[7.11, 0.2]-0.0211 6.55 2.13 2.22 1.92 1.92 1.92 1.93 1.93 1.93 1.93 1.93 1.93 1.93 1.93$												
Heterogeneity, Tat ²⁺ = 0.90, Ch ²⁺ = 268, 60, df = 26, ff = 0.00001); ff = 90% Test for overall effect Z = 7.70 (f < 0.00001) 1.6.2 cm . ⁴ Gaida < 12m, 2004 1.65 2 th 14 - 0.094 1.82 14 1.7% -0.77 [±154, 0.00] Huang ACFL over 2012 1.64 2 m. ⁴ Huang ACFL over 2012 1.65 2 m. ⁴ Huang ACFL over 2012 1.67 2 m. ⁴ Huang ACFL over 2012 1.68 0 to 5 0.99 1.69 0 to 5 0.19 1.79 0 to 5 0.10 0 to 7 1.79 0 to 5 0.10 0 to 7 1.79 0 to 5 0.10 0 to 7 1.79 0 to 5 0.10 0 to	Subtotal (95% CI)	5	4		0.11	2.4				•		
Test for overall effect. $Z = 7.70$ ($P < 0.00001$) 16.2 Gm·19 Gala < 12m 2004 Huang ACCL AP (2017) Huang ACCL AP (2017) Hua		260.60	41-267		00041	- 000	105	45.1 %	- 1.55 [- 1.54, - 1.15]			
$ \begin{array}{c} 1.62 \text{ Gm} - 1 \\ \text{Gaids} < 12m 2004 & -1.65 & 2.1 & 14 & -0.094 & 182 & 14 & 17\% & -0.77 [+1.54, 0.00] \\ \text{Huang ACFL on V2021 } 7.8 & 0.6 & 12 & 13.8 & 0.6 & 12 & 0.8\% & -9.66 [+7.55, -6.56] \\ \text{Huang ACFL on V2021 } 4.5 & 0.4 & 12 & 13.5 & 0.7 & 12 & 0.4\% & +15.24 (+20.03, -10.68) \\ \text{No 2022 } 0 & 0.41 & 18 & 0.05 & 0.99 & 88 & 18\% & -0.07 [+1.24, -0.16] \\ \text{No ed Fulga 7020 } 0.86 & 1.09 & 25 & 8.88 & 2.14 & 25 & 1.7\% & -0.31 (+32, -0.56) \\ \text{Kined Fulga 7020 } 0.86 & 1.09 & 25 & 8.88 & 2.14 & 25 & 1.7\% & -0.31 (+3.0.62) \\ \text{Hole 2020 } 0.2021 & 7.17 & 2.02 & 3.25 & 1.64 & 31 & 18\% & -0.07 [+1.63, -0.62] \\ \text{Malvizzak 2021 } 1.42.66 & 5.98 & 2.5 & 28.83 & 9.21 & 25 & 1.8\% & -1.085 (+2.52, -1.18] \\ \text{Malvizzak 2021 } 1.42.66 & 5.98 & 2.5 & 28.3 & 9.21 & 25 & 1.8\% & -0.48 (+0.051) \\ \text{Zuccaro C12m 2018 } 6.52 & 2.34 & 3.65 & 1.09 & 3.64 & 18\% & -0.04 (+0.051) \\ \text{Zuccaro C12m 2018 } 6.52 & 2.34 & 3.65 & 1.07 & 3.65 & 1.8\% & -0.07 (+1.04, 0.10) \\ \text{Ernelegy 2018 } 1.8 & 1.1 & 65 & 7.5 & 1.9 & 65 & 1.8\% & -0.07 (+1.04, 0.10) \\ \text{Ernelegy 2018 } 1.8 & 1.1 & 65 & 7.5 & 1.9 & 65 & 1.8\% & -0.07 (+1.04, 0.10) \\ \text{Ernelegy 2018 } 1.8 & 1.1 & 65 & 7.5 & 1.9 & 65 & 1.8\% & -0.07 (+1.04, 0.10) \\ \text{Ernelegy 2018 } 1.8 & 0.12 & 1.07 & 0.21 & 7.4 & 2.1 & 1.8\% & -0.02 (+0.0001), F= 95\% \\ \text{Test for varial effect 22 = 5.80 (P < 0.00001) \\ \text{Heirogeneity Tau' = 2.11 (Ch' = 2.24 . 3.12 & 1.10 & 2.1 & 1.8\% & -0.02 (+0.6, 0.19) \\ \text{Lei 3m - 6m 2015 } 8.2 & 1.25 & 1.22 & 1.2 & 1.5\% & -0.04 (+0.0.19) \\ \text{Lei 3m - 6m 2015 } 8.2 & 1.25 & 1.22 & 1.12 & 3.5 & 1.7\% & -0.01 (+0.0.19) \\ \text{Lei 3m - 6m 2015 } 8.2 & 1.25 & 1.22 & 1.0 & 2.2 & 1.00 & 3.00 (+0.001) \\ \text{Lei 3m - 6m 2021 } 6.52 & 2.24 & 6.02 & 3.304 & 4.65 & 2.3 & 1.8\% & -0.07 (+1.11, 0.301) \\ \text{Li 2022 } 2.64 & 8.6 & 3.3.04 & 4.72 & 5.24, -4.21 \\ \text{Li 2021 } 7.7 & 2.2 & 6.9 & 9.2 & 1.50 & 1.8\% & -0.04 (+0.0.19) \\ \text{Li 2022 } 2.64 & 8.6 & 5.7 & 0.9 & 9.3 & 1.8\% & -0.04 (+0.0.10) \\ \text{Li 2022 } 2.64 & 8.6 & 5.7 & 0.9 & 9.3 & 1.8\% & -0.04 (+0.0.001) \\ \text{Li 2021 } 7.8 & 2$				P < 0.0	10001); 1-	-= 90%						
Gaida < 12m 2004	Test for overall effect $Z = 7.70$ (P	< 0.00001	0									
Gaida < 12m 2004	1.6.2.6m-1v											
$\begin{aligned} \begin{aligned} & \text{Hamp} ACFL only 2021 & 7.8 & 0.6 & 12 & 7.3 & 0.6 & 12 & 0.8 & 9.66 [+27.5, 6.56] \\ & \text{Hamp} ACFL only 2021 & 4.5 & 0.4 & 12 & 13.5 & 0.7 & 12 & 0.48 & -0.07 [+0.30, 0.26] \\ & \text{Kerm Elight 2021 } & 0.41 & 0.3 & 21 & 0.71 & 0.43 & 21 & 1.8 & -0.07 [+0.30, 0.26] \\ & \text{Kerm Elight 2020 } & 2.08 & 0.86 & 1.09 & 25 & 9.12 & 1.33 & 25 & 1.58 & -6.19 [+7.57, 4.61] \\ & \text{Lisc Mark 2020 } & 3.66 & 1.09 & 25 & 9.12 & 1.13 & 25 & 1.68 & -1.07 [+3.3, 0.22] \\ & \text{Kare Elight 2020 } & 3.66 & 1.09 & 25 & 9.12 & 1.18 & 1.08 & -1.07 [+3.3, 0.22] \\ & \text{Maluszack 2021 } & 1.42 & 0.58 & 25 & 28.83 & 9.21 & 25 & 1.8 & 3.18 & -0.48 (-0.98, -0.01] \\ & \text{Lasc mark 2021 } & 7.17 & 2.02 & 4.8 & 0.53 & 20 & 8.62 & 0.54 & 20 & 1.38 & -6.91 [+8.2, -2.01] \\ & \text{Maluszack 2021 } & 4.66 & 0.53 & 20 & 8.62 & 0.54 & 20 & 1.38 & -6.91 [+8.62, -5.01] \\ & \text{Maluszack 2021 } & 4.66 & 0.53 & 20 & 8.62 & 0.54 & 20 & 1.38 & -0.47 [+0.4, 0.51] \\ & \text{Subtotal (9% C) } & -5.99 (P < 0.00001) \\ & \text{Lasc mark 2} = 5.99 (P < 0.00001) \\ & \text{Lass than 6m } \\ & \text{Asharnoub 1018 } & -0.18 & 0.57 & 15 & 0.09 & 0.76 & 15 & 1.7\% & -0.13 [+0.85, 0.59] \\ & \text{Ehid 2017 } & -1.168 & 2.05 & 24 & 0.02 & 1.91 & 55 & 1.8\% & -0.47 [+1.4, 0.01] \\ & \text{La 3m -6m 2015 } & 3.2 & 1.25 & 1.26 & 3.3 & 4.14 (-2.93 - 3.14] \\ & \text{Ge 2008 } & 6.503 & 18.19 & 21 & 70.03 & 17.49 & 21 & 1.8\% & -0.22 [+1.46, -0.19] \\ & \text{La 3m -6m 2015 } & 7 & 1.1 & 35 & 1.7\% & -0.31 [+0.85, 0.59] \\ & \text{La 3m -6m 2015 } & 7 & 1.1 & 35 & 1.7\% & -0.31 [+0.85, 0.59] \\ & \text{La 3m -6m 2015 } & 7 & 1.1 & 35 & 1.7\% & -0.31 [+0.85, 0.59] \\ & \text{La 3m -6m 2015 } & 7 & 1.1 & 35 & 1.7\% & -0.31 [+0.85, 0.59] \\ & \text{La 3m -6m 201 } & 6.52 & 2.24 & 6.8 & 2.3 & 1.86 & 3.18 & 5.7 & 7.8 & 2.5 [+1.44, -0.19] \\ & \text{La 3m -6m 201 } & 6.52 & 2.76 & 9.2 & 9.35 & 1.66 & 9.18\% & -0.75 [+1.30, 0.10] \\ & \text{La 3m -6m 201 } & 6.52 & 2.76 & 9.8 & 9.8 & 9.8 & 1.18 & 1.75 & 1.78 & -0.36 [+2.3, -0.21] \\ & \text{La 3m -6m 2021 } & 7.5 & 2.5 & 7.6 & 9.2 & 0.2 & 2.5 & 1.8\% & -0.5 [+2.3, -1.61] \\ & \text{La 3m -6m 2021 } & 7.5 & 2.5 & 7.6 &$		1.65	2.1	1.4	0.004	1.02	14	1 7%	0.771.1.64.0.001	_		
$\begin{aligned} \begin{aligned} & uan_0 FCL + k_1^2(22) & 4.5 & 0.4 & 12 & 13.5 & 0.7 & 12 & 0.4\% + 15.24 + 20.03, 10.49 & \\ & uan_0 FCL + k_1^2(22) & 0.41 & 0.3 & 21 & 0.71 & 0.43 & 21 & 18\% & -0.79 + 1.42, -0.136 & \\ & wan_0 FCL + k_1^2(22) & 0.41 & 0.3 & 21 & 0.71 & 0.43 & 21 & 18\% & -0.79 + 1.42, -0.136 & \\ & wan_0 FCL + k_1^2(22) & 0.41 & 0.3 & 21 & 0.71 & 0.43 & 21 & 18\% & -0.79 + 1.42, -0.161 & \\ & wan_0 FCL + k_1^2(22) & 0.41 & 0.3 & 21 & 0.71 & 0.43 & 21 & 18\% & -0.79 + 1.42, -0.161 & \\ & wan_0 FCL + k_1^2(22) & 0.41 & 0.52 & 0.58 & 0.58 & 21.4 & 25 & 1.7\% & -2.91 + 3.72, -2.10 & \\ & wan_0 FCL + k_1^2(22) & 1.71 & 2.02 & 4.3 & 9.25 & 1.81 & 4.3 & 1.8\% & -1.07 + 1.53, -0.62 & \\ & wan_0 FCL + k_1^2(22) & 1.41 & 26 & 5.08 & 2.58 & 0.52 & 2.52 & 0.58 & -1.08 + 6.25, -2.11 & \\ & Tan 6 - 1/2m & 2021 & 7.9 & 1.7 & 34 & 9.8 & 1.9 & 34 & 1.8\% & -0.49 + 0.68, -0.59 & \\ & wan_0 FCL + k_1^2(22) & 1.81 & 4.3 & 1.8\% & -0.19 + 0.68, 0.59 & \\ & wan_0 FCL + k_1^2(22) & 1.10 & 0.57 & 15 & -0.09 & 0.76 & 15 & 1.7\% & -0.13 + 0.65, 0.59 & \\ & wan_0 FCL + k_1^2(22) & 1.10 & 0.57 & 15 & -0.09 & 0.76 & 15 & 1.7\% & -0.13 + 0.65, 0.59 & \\ & wan_0 FCL + k_1^2(22) & 0.00001 & wan_0 FCL + 1.8\% & -0.27 + 1.04, 0.10 & \\ & wan_0 FCL + k_1^2(23) & 0.11 & 0.57 & 1.5 & 1.25 & 1.8\% & -0.37 + 1.04, 0.10 & \\ & wan_0 FCL + k_1^2(23) & 0.15 & 0.09 & 0.76 & 1.5 & 1.7\% & -0.13 + 0.65, 0.59 & \\ & wan_0 FCL + k_1^2(23) & 0.15 & 0.09 & 0.76 & 1.5 & 1.7\% & -0.13 + 0.65, 0.59 & \\ & wan_0 FCL + k_1^2(23) & 0.15 & 0.09 & 0.76 & 1.5 & 1.7\% & -0.13 + 0.95, 0.59 & \\ & wan_0 FCL + k_1^2(23) & 0.15 & 0.09 & 0.76 & 1.5 & 1.7\% & -0.13 + 0.05, 0.59 & \\ & wan_0 FCL + k_1^2(23) & 0.15 & 0.09 & 0.76 & 1.5 & 1.7\% & 0.13 + 0.05, 0.59 & \\ & wan_0 FCL + k_1^2(23) & 0.15 & 0.05 & 0.01 & wan_0 & 0.01 & \\ & wan_0 FCL + 0.00001 & 1.00 & 0.76 & 1.00 & 0.01 & \\ & wan_0 FCL + 0.00001 & 1.00 & 0.75 & 1.17 & 0.13 & 0.05 & 0.01 & wan_0 & 0.05 & 0.01 & wan_0 & 0.01 & 0.05 & 0.01 & wan_0 & 0.01 & 0.05 & 0.01 & wan_0 & 0$												
$ \begin{array}{c} \mbox{Joc} 2022 & 0 & 0.41 & 08 & 0.05 & 0.99 & 08 & 18\% & -0.07 [0.36, 0.21 \\ \mbox{Kmap} Dohan 2021 & 0.41 & 0.3 & 21 & 0.71 & 0.43 & 21 & 13\% & -0.74 [1.42, -0.16] \\ \mbox{Kmap} Dohan 2021 & 0.46 & 0.26 & 0.26 & 25 & 121 & 1.33 & 25 & 1.5\% & -6.19 [7.57, -4.01] \\ \mbox{Li} Display 2020 & 2.06 & 0.26 & 25 & 122 & 1.32 & 25 & 1.5\% & -6.19 [7.57, -2.01] \\ \mbox{Li} Display 2021 & 7.17 & 2.02 & 43 & 9.25 & 1.81 & 43 & 1.8\% & -1.07 [1.53, -0.62] \\ \mbox{Li} Display 2021 & 7.17 & 2.02 & 43 & 9.25 & 1.81 & 43 & 1.8\% & -0.49 [1.08, -0.61] \\ \mbox{Li} Display 2021 & 4.85 & 0.53 & 20 & 9.62 & 0.54 & 20 & 1.3\% & -6.91 [1.86, -0.61] \\ \mbox{Li} Display 2021 & 4.85 & 0.53 & 20 & 9.62 & 0.54 & 20 & 1.3\% & -6.91 [1.86, -0.61] \\ \mbox{Li} Display 21 & 7.17 & 2.02 & 4.3 & 9.17 & 9.5 & 55 & 18.3\% & -2.72 [1.362, -1.81] \\ \mbox{Li} Display 21 & 7.018 & 6.52 & 2.34 & 0.22 & 1.91 & 25 & 1.8\% & -0.47 [1.04, -0.51] \\ \mbox{Subtat} (95\% C) & -0.18 & 0.57 & 15 & -0.09 & 0.76 & 15 & 1.7\% & -0.13 [-0.85, 0.59] \\ \mbox{End} (95\% C) & -1.18 & 0.57 & 15 & -0.09 & 0.76 & 15 & 1.7\% & -0.13 [-0.85, 0.59] \\ \mbox{End} (95\% C) & -1.18 & 0.57 & 15 & -0.09 & 0.76 & 15 & 1.7\% & -0.3 [-0.85, 0.59] \\ \mbox{End} (95\% C) & -0.0001) \\ \mbox{Less than 6m} \\ Le$												
Kerne Bohan 2021 0.41 0.3 21 0.71 0.43 21 1.8% $-0.79 [1.42, 0.16]$ Kheel Kulpi V200 2.08 0.66 25 9.12 1.33 25 1.5% $-6.19 [1.42, 0.16]$ $J \ge 6m. 2021$ 7.17 2.02 43 9.25 1.81 43 18% $-1.07 [1.63, 0.62]$ Maturazaka 2021 14.26 5.08 25 28.3 9.21 25 1.8% $-1.86 [1.63, 0.62]$ Tan 6 $-12m. 2021$ 7.9 1.7 34 0.80 9.9 34 1.8% $-0.07 [1.63, 0.62]$ Tan 6 $-12m. 2021$ 7.9 1.7 34 0.80 9.9 34 1.8% $-0.07 [1.63, 0.62]$ Juccano 2021 4.85 0.53 20 0.62 0.54 20 1.3% $-6.91 [1.86, 2.520]$ Juccano 2021 4.85 0.53 20 0.62 0.54 20 1.3% $-6.91 [1.86, 2.520]$ Juccano ($-12m. 2018$ 6.52 2.34 36 8.63 1.79 36 1.8% $-1.00 [1.42, 0.51]$ Helerogeneity. Tat" $= 2.11$, ChT $= 2.34.34$, df $= 11 (P < 0.00001)$, $P = 95\%$ Tastfor overall effect $Z = 5.69 (P < 0.00001)$ Testfor overall effect $Z = 5.69 (P < 0.00001)$, $P = 95\%$ Tastfor overall effect $Z = 5.69 (P < 0.00001)$ Lei 3m $-5m. 2015$ 2.1 25 1.7% $-4.31 [5.23, -4.34]$ Lei 3m $-3m. 2015$ 7.1 1.65 2.27 1.9 25 1.8% $-0.47 [1.64, 0.10]$ I = 0.30016 7.1 1.36 1.24 1.3 35 1.7% $-4.31 [5.23, -2.56]I = 0.30016$ 7.1 1.36 1.24 1.3 35 1.7% $-4.34 [5.23, -2.56]I = 0.30016$ 7.1 1.36 1.24 1.3 35 1.7% $-4.34 [5.23, -2.56]I = 0.30016$ 7.1 1.36 1.24 1.3 35 1.8% $-0.72 [1.11, -0.32]I = 0.30015$ 7.1 1.36 1.24 1.3 35 1.8% $-0.72 [1.11, -0.32]I = 0.30016$ 7.1 1.36 1.24 1.3 35 1.1% $-1.56 [1.3, -1.17]I = 0.221$ 6.65 2.73 53 0.42 1.8 1.3 112 (1.18% $-4.72 [2.54, 4.21]I = 0.2018$ 3.0 9 1.1 9 1.1 31 112 (1.18% $-4.72 [2.54, 4.21]I = 0.2018$ 3.1 0.9 1.1 9 1.1 9 1.7% $-0.28 [3.26, 1.48]I = 6m. 2021$ 7.6 2.6 37 8.9 1.9 37 1.8% $-0.72 [1.11, -0.30]I = 0.56 [1.03, -0.10]I = 0.21$ 7.7 2.2 50 9.2 2.50 1.9% $-0.71 [1.11, -0.30]I = 0.56 [1.03, -0.10]I = 0.56 [1.03, -0.10]I = 0.56 [1.03, -0.10]I = 0.56 [1.03, -0.01]I = 0.56 [1.03, -0.01]$									-15.24 [-20.03, -10.46]			
Kheider Highn 2020 2.08 0.86 25 9.12 1.33 25 1.5%, $-6.19 [7.67, 4.91]$ L) > $m 2021$ 7.17 2.02 43 9.25 1.81 43 1.8%, $-107 [1.53, 0.62]$ Tan $6 - 12m 2021$ 7.17 2.02 43 9.25 1.81 43 1.8%, $-107 [1.53, 0.62]$ Tan $6 - 12m 2021$ 7.17 2.02 43 9.25 1.81 43 1.8%, $-107 [1.53, 0.62]$ Tan $6 - 12m 2021$ 7.8 48 0.65 2.28 9.21 25 1.8%, $-186 [1.62, 5.20]$ Tan $6 - 12m 2021$ 4.85 0.55 2.0 8.62 0.54 2.0 1.3%, $-631 [1.62, 5.20]$ Zuccano 2.01 4.85 0.55 2.0 8.62 0.54 2.0 1.3%, $-631 [1.62, 5.20]$ Zuccano 2.12m 2018 6.52 2.34 3.6 6.53 1.79 355 1.8.%, $-1.00 [1.49, 0.51]$ Subtotal (9%) (0) 355 355 18.19 42 1.78%, $-0.47 [1.04, 0.51]$ Alteragenety, Tau" = 2.11; ChF = 2.34 4.3, df = 11 ($P < 0.00001$); $P = 95\%$ Testfor overall effect $Z = 5.89$ ($P < 0.00001$) Test $2 = 2.28 (P < 0.0001)$ Li $3 = 2.2 = 2.28 (P < 0.0001)$ Li $3 = 0.87 (1.429, -3.14]$ = 0.42 (1.429, -3.14] = 0.42 (1.419, -3.16] = 0.42 (1.419, -3.16]									-0.07 [-0.36, 0.23]			
Khedr M2 2020 3.86 109 25 8.88 2.14 25 1.7% -2.91 [3.72, -2.10] $l \ge 6m 2021$ 7.17 2.02 43 9.25 1.81 43 18% -1.07 [1.63, -0.62] Maluzczak 2021 14.26 5.98 25 28.3 9.21 25 1.8% -1.85 [2.52, -1.18] Tan 6 - 12m 2021 7.9 1.7 34 8.8 9 34 19% -0.49 [0.98, -0.01] Zuccara 2021 4.85 0.53 20 9.62 0.54 20 1.3% -63 [1.96.2, -5.20] Zuccara (2m 2018 6.52 2.34 3.6 e1.1 (P < 0.0001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001) Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.89$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.90$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.00$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.00$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.00$ (P < 0.00001), P = 95% Test for versal effect $Z = 5.00$ (P < 0.00001), P = 95% Test for versal effect $Z = 1.520$ (P < 0.00001), P = 95% Test for versal effect $Z = 1.520$ (P < 0.00001), P = 95% Test for versal effect $Z = 1.520$ (P < 0.00001), P = 95% Test for versal effect $Z = 1.520$ (P < 0.00001), P = 95% Test for versal effect $Z = 1.520$ (P < 0.00001), P = 95% Test for versal effect $Z = 1.520$ (P < 0.00001), P = 95% Test for versal effect $Z = 1.520$ (P <												
$\begin{split} \square > 6m 2021 & 7.17 & 2.02 & 43 & 9.25 & 1.61 & 43 & 18\% & -1.07 [+ 1.63, -0.62] \\ \hline Maturaczak 2021 & 12.6 & 52 & 2.34 & 8.8 & 19 & 34 & 18\% & -0.49 [-0.85, -0.11] \\ \hline Tan 6 - 12m 2021 & 7.9 & 1.7 & 34 & 8.8 & 19 & 34 & 18\% & -0.49 [-0.85, -0.11] \\ \hline Tan 6 - 12m 2021 & 4.55 & 0.52 & 0.8 & 6.2 & 0.54 & 2.0 & 1.3\% & -6.91 [+6.82, -5.20] \\ \hline Zuccara 2021 & 4.55 & 0.52 & 0.8 & 6.2 & 0.55 & 18.3\% & -2.72 [-3.62, -1.81] \\ \hline Maturaczak 20(1) & 4.52 & 2.34 & 3.66 & 6.3 & 1.79 & 36 & 1.8\% & -1.00 [+1.49, -0.51] \\ \hline Subtotal (95\% C) & 355 & 10.35 & 10.3\% & -6.91 [+6.82, -5.20] \\ \hline Acharanoub (2018 & -0.18 & 0.57 & 15 & -0.09 & 0.76 & 15 & 1.7\% & -0.13 [+0.85, 0.59] \\ \hline Ehid 2017 & -1.168 & 2.05 & 2.4 & -0.22 & 1.91 & 25 & 1.8\% & -0.47 [+1.04, -0.10] \\ \hline Ehid 2017 & -1.168 & 2.05 & 2.4 & -0.22 & 1.91 & 55 & 18\% & -0.47 [+1.42, -3.14] \\ \hline Ge 2008 & 5.03 & 18.19 & 21 & 70.03 & 17.49 & 21 & 1.8\% & -0.32 [+1.46, -0.19] \\ \hline Elai 2015 & 7 & 1.1 & 35 & 12.4 & 1.3 & 35 & 1.7\% & -4.43 [+5.23, -3.55] \\ \Box = -3m 2015 & 7 & 1.1 & 35 & 1.24 & 1.3 & 35 & 1.7\% & -4.43 [+5.24, -4.21] \\ \Box = -3m 2015 & 7 & 1.1 & 35 & 1.5\% & 6.9 & 1.8\% & -7.25 [+1.3, -1.17] & -1.16 \\ \Box = -0.221 & 6.52 & 2.28 & 69 & 9.36 & 1.56 & 69 & 1.8\% & -1.55 [+1.3, -1.17] & -1.16 \\ \Box = -0.221 & 6.52 & 2.76 & 0.9 & 2.6 & 1.9\% & -1.7\% & -7.08 [+2.32, -4.42] \\ \Box = -0.221 & 6.52 & 5.1 & 9.9 & 1.9 & 1.9 & 1.7\% & -7.08 [+2.32, -4.42] \\ \Box = -0.221 & 7.6 & 2.5 & 9.7 & 9.9 & 1.9 & 9.7 & 1.8\% & -0.56 [+1.03, -10] \\ \Box = -0.21 & 7.6 & 2.5 & 9.9 & 9.8 & 1.9 & 9.7\% & -7.08 [+2.32, -6.21] \\ Tan 1 - 3m 2021 & 7.6 & 2.5 & 9.9 & 9.8 & 1.9 & 9.7\% & -7.08 [+2.32, -1.48] \\ Tan - 3m 2021 & 7.6 & 2.6 & 37 & 9.9 & 1.9 & 37 & 1.8\% & -0.56 [+1.03, -10] \\ \Box = -0.201 & 7.6 & 2.6 & 37 & 9.9 & 1.9 & 37 & 1.8\% & -0.56 [+0.3, -0.0] \\ Tan 3 - 6m 2021 & 7.6 & 2.1 & 221 & 10.2 & 2 & 221 & 19\% & -2.53 [+2.7, -2.28] \\ Tan - 3m 2021 & 7.6 & 2.1 & 221 & 10.2 & 2 & 221 & 1.9\% & -0.56 [+0.3, -0.0] \\ Tan - 3m 2021 & 7.6 & 2.1 & 221 & 10.2 & 2 & 221 & 1.9\% & -0.56 [+0.3, -0.0] \\ Tan - 5m 2021 & 7.6 & 2.6 & 3$												
$ \begin{aligned} \text{Maluzzak} 2021 & 14.26 & 5.98 & 25.28.3 & 9.21 & 25 & 18.\% & -1.85 \left[2.52, -1.18\right] \\ \text{Tan 6} - 127021 & 7.9 & 17.3 & 8.8 & 9.34 & 19.34 & 19.5 & 19.36 & 19.635.01 \\ \text{Zuccaro} 2021 & 4.85 & 0.53 & 20 & 6.63 & 1.79 & 36 & 18.\% & -0.01 \left[+4.9, -0.51\right] \\ \text{Zuccaro} (-127, -217, -214, -23, -43, -61+1) \left(P - 0.00001\right), P = 95\% \\ \text{Subtactal} (95\%, -0.00001) \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.89 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.99 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.99 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.99 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.0001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.0001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.0001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.0001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.0001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.0001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 (P - 0.00001), P = 95\% \\ \text{Test for versal intert } 2 = 5.01 ($												
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Li > 6m 2021	7.17	2.02	43	9.25	1.81	43	1.8%	-1.07 [-1.53, -0.62]	-		
$ \begin{array}{c} 2 \text{Luccan} < 12 \text{ Me} 8 & 0.53 & 20 & 8.62 & 0.54 & 20 & 1.3\% & -6.91 [8.62, -5.20 \\ \text{Subtoal (295K C)} & 355 & 355 & 18.3\% & 2.72 [.3.62, -1.81] \\ Heterogeneity, Tau" = 2.11; ChF = 234.43, df = 11 (P < 0.0001); P = 95\% \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.99 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.90 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.90 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.90 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.90 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 5.00 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P < 0.00001) \\ \text{Test for versal iffect 2 Z = 1.59 (P <$	Matuszczak 2021		5.98	25	28.83	9.21	25	1.8%	-1.85 [-2.52, -1.18]	-		
$ \begin{array}{c} \mbox{2ucca} < 12m 2018 & 6.52 & 2.34 & 36 & 8.63 & 1.79 & 36 & 1.8\% & -1.00 [+1.49, -0.61] \\ \mbox{Helerogeneity}. Tau" = 2.11; ChF = 224.43, df = 11 (P < 0.00001); P = 95\% \\ \mbox{Test for overall effect Z = 5.89 (P < 0.00001) \\ \mbox{1.63} Less than 6m \\ \mbox{Alshanoubi 2018 & -0.19 & 0.57 & 15 & -0.09 & 0.76 & 15 & 1.7\% & -0.13 [+0.65, 0.59] \\ \mbox{End 107 } & -1.168 & 2.05 & 24 & -0.22 & 1.91 & 25 & 1.8\% & -3.71 [+1.42, -3.14] \\ \mbox{Cell 2017 } & -1.168 & 2.05 & 24 & -0.22 & 1.91 & 25 & 1.8\% & -3.71 [+1.42, -3.14] \\ \mbox{Cell 2018 } & 5.03 & 18.19 & 21 & 70.03 & 17.49 & 21 & 1.8\% & -3.72 [+1.45, -0.19] \\ \mbox{Cell 2018 } & 5.03 & 18.19 & 21 & 70.03 & 17.49 & 21 & 1.8\% & -0.82 [+1.45, -0.19] \\ \mbox{Cell 2018 } & 5.03 & 18.19 & 21 & 70.03 & 17.49 & 21 & 1.8\% & -0.82 [+1.45, -0.19] \\ \mbox{Cell 2018 } & 5.03 & 0.32 & 1.2 & 51 & 1.35 & 1.7\% & -4.43 [+5.23, -3.56] \\ \mbox{Le 13 w - m 2015 } & 7 & 1.1 & 35 & 1.24 & 1.3 & 35 & 1.7\% & -4.43 [+5.23, -3.56] \\ \mbox{Le 14 W - m 2021 } & 6.52 & 2.22 & 6.69 & 9.36 & 1.56 & 6.9 & 1.8\% & -1.55 [+1.3], -1.17 & -1.16 & -1.14 [+7.6, -0.51] \\ \mbox{Le 16 2022 } & 2.648 & 6.6 & 2.3 & 3.04 & 4.56 & 2.3 & 1.8\% & -1.14 [+1.76, -0.51] \\ \mbox{Le 17 W - 2018 } & 3.5 & 0.6 & 99 & 9.8 & 1.9 & 91 & 7\% & -7.08 [+3.26, -1.48] \\ \mbox{Le 0 201 } & 7.6 & 2.6 & 37 & 0.9 & 1.9 & 37 & 1.8\% & -0.45 [+0.33, -0.0] \\ \mbox{La 1 - 6m 2021 } & 7.6 & 2.6 & 37 & 0.9 & 1.9 & 37 & 1.8\% & -0.45 [+0.33, -0.0] \\ \mbox{La 1 - 6m 2021 } & 7.6 & 2.6 & 37 & 0.9 & 1.9 & 37 & 1.8\% & -0.45 [+0.33, -0.0] \\ \mbox{La 2018 } & 5 & 2.1 & 221 & 10.2 & 2 & 221 & 1.9\% & -3.25 [+0.36, -0.0] \\ \mbox{Ma 2018 } & 5 & 2.1 & 221 & 10.2 & 2 & 2.21 & 1.9\% & -3.25 [+2.3, -2.2] & -1.17 & -1.$	Tan 6 – 12m 2021	7.9	1.7	34	8.8	1.9	34	1.8%	-0.49 [-0.98, -0.01]	-		
Subtotal (95% Cl) 355 355 18.3% 2.72 [3.62, -1.81] Heterogeneity. The 2.311, ChF = 234 43, df = 11 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 5.89 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 5.89 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 5.89 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 5.89 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 5.89 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 15.99 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 15.99 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 15.99 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$ Test for overall effect 2 = 10.59 ($P < 0.00001$), $P = 95\%$	Zuccaro 2021	4.85	0.53		8.62	0.54	20	1.3%	-6.91 [-8.62, -5.20]			
Subtotal (95% Cl) 355 355 18.3% 2.72[.3.62, 1.81] Heterogenety. The 2.311; $(Ch^2 = 234.43, df = 11 (P < 0.00001); P = 95%$ Test for overall effect 2 = 5.89 (P < 0.00001) 1.6.3 Less than 6m Alsharmoubi 2016 -0.19 0.57 15 -0.09 0.76 15 1.7% -0.13 [-0.65, 0.59] Eli 3017 -1.168 2.05 24 0.22 1.91 25 1.8% -0.47 [-1.04, 0.10] Eli melegy 2018 1.8 1.1 65 7.6 1.9 65 1.8% -0.37 [+1.42, 9.314] Ce 2008 5.05 31 8.19 21 700 17.49 21 1.8% -0.32 [+1.46, 0.19] 	Zuccaro < 12m 2018	6.52	2.34	36	8.63	1.79	36	1.8%	-1.00 [-1.49, -0.51]	-		
Testfor overall effect $Z = 5.89$ (P < 0.00001) 1.6.3 Less than 6m Alshamoub/2010 0 018 057 15 009 076 15 17% 013 {0.05, 0.59} Endegr 2016 1.8 1.1 65 7.6 1.9 65 1.8% 0.47 {1.04, 0.10} Ennelegr 2016 1.8 1.1 65 7.6 1.9 65 1.8% 0.47 {1.42, 9.314} Ce 2008 5503 18.19 21 700 17.49 21 1.9% 0.02 {1.46, 0.19} La 3m - 6m 2015 2.2 1 25 1.2 1.2 5 1.6% 0.394 {1.43, 2.53} L0 - 3m 2021 6.65 2.73 53 8.32 1.81 53 1.8% 0.72 {1.11, 0.33} L1 4 - 6m 2016 3.8 0.9 112 91 1.3 112 1.8% 0.42 {1.14, 6.019} L1 4 - 6m 2011 6.32 2.26 69 9.36 1.56 69 1.8% 0.72 {1.11, 0.33} L1 4 - 6m 2012 6.32 2.26 69 9.36 1.56 69 1.8% 0.72 {1.11, 0.33} L1 4 - 6m 2021 6.32 2.26 69 9.36 1.56 69 1.8% 0.72 {1.11, 0.33} L1 4 - 6m 2021 7.7 2.2 50 9.2 2 50 1.8% 0.71 {1.11, 0.30} Tan 1 - 3m 2021 7.7 2.2 50 9.2 2 50 1.8% 0.71 {1.11, 0.30} Tan 1 - 3m 2021 7.7 2.2 50 9.2 2 50 1.8% 0.71 {1.11, 0.30} Tan 3 - 6m 2021 7.8 2.1 45 8.7 1.9 45 1.8% 0.44 {1.60, 0.01} Vang 20d once per veek 2021 7.6 2.5 37 9.9 1.9 37 1.8% 0.45 {1.03, 0.10} Vang 30d once per veek 2021 5.64 3.34 4 7.12 2.34 4 1.5% 0.41 {1.13, 3.66, 3.20} Vang 30d once per veek 2021 5.64 3.34 4 7.12 3.34 4 1.5% 0.41 {1.43, 3.60, 3.20} Vang 30d once per veek 2021 5.64 3.34 4 7.12 3.34 4 1.5% 0.41 {1.43, 0.091} Vang 30d once per veek 2021 5.64 3.34 4 7.12 3.34 4 1.5% 0.41 {1.43, 0.091} Vang 30d once per veek 2021 5.64 3.34 4 7.12 3.34 4 1.5% 0.41 {1.43, 0.091} Vang 30d once per veek 2021 6.74 3.9 df = 20 (P < 0.00001); P = 97% Test or veenal infect 2 Z = 7.50 (P < 0.00001); P = 97% Test or veenal infect 2 Z = 7.50 (P < 0.00001); P = 97% Test or veenal infect 2 Z = 7.50 (P < 0.00001); P = 96% Test or veenal infect 2 Z = 7.50 (P < 0.00001); P = 96%	Subtotal (95% CI)			355			355	18.3%		•		
1.6.3 Less than $6m$ Alshamoub 2018 0.18 0.13 \downarrow 0.05 (0.59) Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2" Colspan="2">Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" <th <="" colspan="2" td=""><td>Heterogeneity: Tau² = 2.11; Chi² =</td><td>234.43,</td><td>df= 11 (</td><td>P < 0.0</td><td>0001); P</td><td>= 95%</td><td></td><td></td><td></td><td></td></th>	<td>Heterogeneity: Tau² = 2.11; Chi² =</td> <td>234.43,</td> <td>df= 11 (</td> <td>P < 0.0</td> <td>0001); P</td> <td>= 95%</td> <td></td> <td></td> <td></td> <td></td>		Heterogeneity: Tau ² = 2.11; Chi ² =	234.43,	df= 11 (P < 0.0	0001); P	= 95%				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Test for overall effect: Z = 5.89 (P	< 0.00001	1)									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $												
Ebid 20171.168 2.05 24 -0.22 1.91 25 1.8% -0.47 [+1.0], 010 Emellegy 2018 1.8 1.1 65 7.6 19 65 1.8% -3.71 [+2.9, 314] Ge 2008 6503 18.19 21 7003 17.49 21 1.8% -0.82 [+1.42, -3.14] Ge 2008 6503 18.19 21 7003 17.49 21 1.8% -0.82 [+1.42, -3.14] Ge 2008 6503 18.19 21 7003 17.49 21 1.8% -0.82 [+1.42, -3.14] Ge 2008 6503 18.19 21 7003 17.49 21 1.8% -0.82 [+1.42, -3.14] Ge 2018 6503 18.19 21 7003 17.49 21 1.8% -0.82 [+1.42, -3.26] Ge 2016 7 1.1 35 12.4 1.3 35 1.7% -4.43 [5.22, -3.56] U = - U = - - U = - - - - - - - - - - - - - -		1	1									
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$										-		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Ebid 2017	-1.168	2.05	24	-0.22	1.91	25	1.8%	-0.47 [-1.04, 0.10]			
Lei 3m - 5m 2015 12 1 26 12 1 25 16 % - 34 14 91 - 291 Li 3 - 5m 2015 7 11 36 124 13 35 17 4 - 44 31 523 - 356	Elmelegy 2018	1.8	1.1	65	7.6	1.9	65	1.8%	-3.71 [-4.29, -3.14]	-		
$ \begin{array}{c} \text{Lel} 3 \# - 3 m 2015 & 7 & 1.1 & 35 & 12.4 & 1.3 & 35 & 1.7 \% & -4.43 (5 2.2, -35) \\ \text{Lu} - 3 m 201 & 6.55 & 2.7 & 38 & 8.22 & 1.81 & 53 & 1.8 \% & -0.72 (1 + 11, -0.32) \\ \text{Lu} - 4 = 6 m 2021 & 6.32 & 2.28 & 69 & 9.36 & 1.56 & 69 & 1.8 \% & -0.72 (5 2.4, -4.21) \\ \text{Lu} 2012 & 2.28 (48 & 6.5 & 23 & 33.0 & 4.56 & 23 & 1.8 & -5.3 & 1.8 \\ \text{Lu} 2022 & 2.648 & 6.5 & 23 & 33.0 & 4.56 & 23 & 1.8 & -5.3 & 1.8 \\ \text{Lu} 2022 & 2.648 & 6.5 & 23 & 33.0 & 4.56 & 23 & 1.8 \\ \text{Lu} 2021 & 2.20 & 1.8 & 5.1 & 1.8 & 1.7 & .7.8 (5 2.4, -4.21) \\ \text{Lu} = 5 & 0.20 & 1.7 & 9.2 & 50 & 1.8 & -7.1 (1 + 1.7 , -0.51) \\ \text{Lu} = 5 & 0.5 & 0.5 & 9.9 & 9.8 & 1.1 & 99 & 1.7 & -7.0 (5 7.4 , -6.33) \\ \text{Lu} = 5 & 0.5 & 0.5 & 0.5 & 9.9 & 9.8 & 1.1 & 99 & 1.7 & -7.0 (5 7.4 , -6.33) \\ \text{Lu} = 5 & 0.5 & 0.5 & 0.5 & 0.5 & 0.7 & 9.1 & 0.8 & -0.71 (1 + 1.11, -0.01) \\ \text{Tan} - 1 & m 2021 & 7.6 & 2.6 & 7.8 & 9.1 & 9.1 & 9.8 & -0.45 (1 - 0.3 - 0.10) \\ \text{Tan} - 1 & m 2021 & 7.6 & 2.1 & 6.7 & 1.9 & 4.5 & 1.8 & -0.45 (1 - 0.3 - 0.10) \\ \text{Tan} - 1 & m 2021 & 7.8 & 2.1 & 4.5 & 0.7 & 1.9 & 4.5 & 1.8 & -0.45 (1 - 0.8 - 0.3) \\ Yang 2001 once per 2week 2021 & 5.64 & 3.34 & 4 & 7.12 & 3.34 & 4 & 1.5 & -0.34 (1 - 0.3) (1 - 1.33 (1 - 1$	Ge 2008	55.03	18.19	21	70.03	17.49	21	1.8%	-0.82 [-1.46, -0.19]	-		
$ \begin{array}{c} \text{Lel} 3 \# - 3 m 2015 & 7 & 1.1 & 35 & 12.4 & 1.3 & 35 & 1.7 \% & -4.43 (5 2.2, -35) \\ \text{Lu} - 3 m 201 & 6.55 & 2.7 & 38 & 8.22 & 1.81 & 53 & 1.8 \% & -0.72 (1 + 11, -0.32) \\ \text{Lu} - 4 = 6 m 2021 & 6.32 & 2.28 & 69 & 9.36 & 1.56 & 69 & 1.8 \% & -0.72 (5 2.4, -4.21) \\ \text{Lu} 2012 & 2.28 (48 & 6.5 & 23 & 33.0 & 4.56 & 23 & 1.8 & -5.3 & 1.8 \\ \text{Lu} 2022 & 2.648 & 6.5 & 23 & 33.0 & 4.56 & 23 & 1.8 & -5.3 & 1.8 \\ \text{Lu} 2022 & 2.648 & 6.5 & 23 & 33.0 & 4.56 & 23 & 1.8 \\ \text{Lu} 2021 & 2.20 & 1.8 & 5.1 & 1.8 & 1.7 & .7.8 (5 2.4, -4.21) \\ \text{Lu} = 5 & 0.20 & 1.7 & 9.2 & 50 & 1.8 & -7.1 (1 + 1.7 , -0.51) \\ \text{Lu} = 5 & 0.5 & 0.5 & 9.9 & 9.8 & 1.1 & 99 & 1.7 & -7.0 (5 7.4 , -6.33) \\ \text{Lu} = 5 & 0.5 & 0.5 & 0.5 & 9.9 & 9.8 & 1.1 & 99 & 1.7 & -7.0 (5 7.4 , -6.33) \\ \text{Lu} = 5 & 0.5 & 0.5 & 0.5 & 0.5 & 0.7 & 9.1 & 0.8 & -0.71 (1 + 1.11, -0.01) \\ \text{Tan} - 1 & m 2021 & 7.6 & 2.6 & 7.8 & 9.1 & 9.1 & 9.8 & -0.45 (1 - 0.3 - 0.10) \\ \text{Tan} - 1 & m 2021 & 7.6 & 2.1 & 6.7 & 1.9 & 4.5 & 1.8 & -0.45 (1 - 0.3 - 0.10) \\ \text{Tan} - 1 & m 2021 & 7.8 & 2.1 & 4.5 & 0.7 & 1.9 & 4.5 & 1.8 & -0.45 (1 - 0.8 - 0.3) \\ Yang 2001 once per 2week 2021 & 5.64 & 3.34 & 4 & 7.12 & 3.34 & 4 & 1.5 & -0.34 (1 - 0.3) (1 - 1.33 (1 - 1$	Lei 3m – 6m 2015	8.2	1	25	12.2	1	25	1.6%	-3.94 [-4.91, -2.96]			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Lei 3w- 3m 2015	7	1.1	35	12.4	1.3	35	1.7%				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Li 0 – 3m 2021	6.65			8.32	1.81	53	1.8%		-		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Li 4 - 6m 2021	6.32	2.28		9.36	1.56		1.8%				
Liu 2022 2649 66 23 32.04 4.66 23 18% -1.14 [176, -051] U \subseteq CE 2016 35 0.6 99 98 1.1 99 17% -2.8 [F34, -6.33] Tan 1-3m 2021 7.7 2.2 50 9.2 250 18% -0.7 [1.11, 0.30] Tan 1-3m 2021 7.7 2.2 50 9.2 250 18% -0.7 [1.11, 0.30] Tan 3-5m 2021 7.6 2.6 37 8.9 1.9 37 1.8% -0.6 [1.03, -010] Tan 3-5m 2021 7.8 2.1 45 8.7 1.9 4.5 18% -0.45 [1.03, -0.0] Tan 3-1m 2021 7.8 2.1 45 8.7 1.9 4.5 18% -0.45 [1.03, -0.0] Tan 3-1m 2021 7.8 2.1 45 8.7 1.9 4.5 1.9% -0.33 [3.66, -3.0] Tan 3-1m 2021 7.8 2.1 10.2 2.2 2.21 19% -2.53 [2.78, -2.6] - Yang 2022 4.11 0.81 169 7.93 1.4 169 1.8% -0.34 [1.03, 1.00] Tan 30d once per Xweek 2021 5.54 3.34 4 7.12 3.34 4 1.5% -0.44 [1.03, 1.00] Tang 60d once per Xweek 2021 5.64 3.81 5 7.09 3.81 5 1.5% -0.34 [1.03, 1.00] Tang 60d once per Xweek 2021 7.26 1.17 6 9.74 0.39 6 1.3% -2.63 [4.23, 0.91] Tang 60d once per Xweek 2021 7.26 1.17 6 9.74 0.39 6 1.3% -2.63 [4.23, 0.92] Tastor overall effect Z = 10.50 (P < 0.00001), P = 97% Testor overall effect Z = 10.50 (P < 0.00001), P = 96% Testor overall effect Z = 10.50 (P < 0.00001) Total (95% C) Testor overall effect Z = 10.50 (P < 0.00001) Total (95 (C) 0.0001) Testor overall effect Z = 10.50 (P < 0.00001) Testor overall Expect Fourther Lexenter fourther Lexenter fourther Lexenter fourther Lexenter fourther Lexenter fourther Lexenter Lexent	LI PDL 2018									-		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $										_		
$ \begin{array}{ $												
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$												
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$										_		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $												
Xie 2018 5 2.1 221 10.2 2 2.21 19% -2.53 [2.78, -2.28] - Yang 202 4.11 0.81 169 7.93 1.4 169 18% -33 3.966, -3.00] - Yang 30d once per /week 2021 5.54 3.34 4 7.12 3.34 4 1.5% -0.41 [-1.83, 10.0] Yang 60d once per /week 2021 6.73 2.12 6 8.46 1.7 5 1.5% -0.34 [+1.60, 0.91] Yang 60d once per /week 2021 7.26 1.17 6 9.74 0.39 6 1.3% -2.63 [+3.3, 0.92] Subtatal (95% c) -2.48 [-ch = 70.439, df = 20 (P < 0.0001)], P = 97% Total (95% c) 2371 2225 100.0% -1.94 [-2.30, -1.58] Heterogeneity. Tau ² = 1.83; Ch P = 1335, 95, df = 50 (P < 0.00001)], P = 96% Total (95% c) - 10 - 5 0 5 10 Eastror versal infect 2.2 = 5.76 (P < 0.00001)], P = 96% Total (95% c) - 10 - 5 0 5 10 Eastror versal infect 2.2 = 0.50 (P < 0.00001)], P = 96%												
Yang 2022 4.11 0.81 169 7.93 1.4 169 1.8% -3.33 1.36,6,300 - Yang 30d once per week 2021 5.64 3.84 7.12 3.34 4 1.5% -0.41 [+1.83,1.00] Yang 60d once per 3week 2021 5.64 3.81 5 7.09 3.81 5 1.5% -0.34 [+1.83,1.00] Yang 60d once per 4week 2021 6.73 2.12 5 8.46 1.7 6 1.5% -0.81 [+2.13,0.51] Yang 60d once per 4week 2021 1.72 1.17 6 9.74 0.39 6 1.5% -0.81 [+2.13,0.51] Subtotal (95% CI) 1.72 1.17 6 9.74 0.39 6 1.5% -0.81 [+2.13,0.51] Heterogenety. Tau ² = 4.8; Ch ² = 1.33 6.95 (f < 0.00001); I ² = 97% Test for overall effect 2 = 1.50 (f < 0.00001) Total (95% CI) 2.371 2.225 100.0% -1.94 [+2.30, -1.58] Heterogenety. Tau ² = 1.83; Ch ² = 1.33 6.95 (f < 0.00001); I ² = 96% Test for overall effect 2 = 1.50 (f < 0.00001) Total (95% CI) 2.371 2.225 100.0% -1.94 [+2.30, -1.58] +0 - 10 - 5 0 5 10 Estimate lange	1 au ~ 111 2021											
Yang 300 once per week 2021 5.64 3.34 4 7.12 3.34 4 1.5% -0.41 [+183,100] Yang 600 once per 2week 2021 5.64 3.81 5 7.09 3.81 5 1.5% -0.81 [+160,091] Yang 600 once per 3week 2021 6.73 2.12 5 8.45 1.7 5 1.5% -0.81 [+2.13,051] Yang 600 once per 4week 2021 7.26 1.17 6 9.74 0.39 6 1.3% -2.65 [+2.3,0-92] Subtatal (95% Ct) -2.05 [+2.74, -1.35] Heterogenetik: Tau [#] = 2.48; Ch [#] = 704.39, df = 20 (P < 0.00001); I [#] = 97% Total (95% Ct) -2.71 2225 100.0% -1.94 [+2.30, -1.58] Heterogenetik: Tau [#] = 1.83; Ch [#] = 1.35, 95, df = 50 (P < 0.00001); I [#] = 96% Total (95% Ct) -10 -5 0 5 10 Heterogenetik: Tau [#] = 1.83; Ch [#] = 1.35, 95, df = 50 (P < 0.00001); I [#] = 96% Testfor overall effect Z = 1.50 (P < 0.00001) Heterogenetik: Tau [#] = 1.83; Ch [#] = 1.35, 95, df = 50 (P < 0.00001); I [#] = 96% Testfor overall effect Z = 1.50 (P < 0.00001) Heterogenetik: Tau [#] = 1.83; Ch [#] = 1.35, 95, df = 50 (P < 0.00001); I [#] = 96% Testfor overall effect Z = 1.50 (P < 0.00001) Heterogenetik: Tau [#] = 1.83; Ch [#] = 1.35, 95, df = 50 (P < 0.00001); I [#] = 96% Testfor overall effect Z = 1.50 (P < 0.00001) Heterogenetik: Tau [#] = 1.83; Ch [#] = 1.93; 95, df = 50 (P < 0.00001); I [#] = 96% Testfor overall effect Z = 1.50 (P < 0.00001)												
Yang 60 d once per 2week 2021 5 64 3 81 5 7 09 3 81 5 1 5% -0.34 [+160,0.91] Yang 60 d once per 3week 2021 6 73 2.12 5 8.46 1.7 5 1.5% -0.81 [+2.13,051] Yang 60 d once per 4week 2021 7.26 1.17 6 97 4 0.93 6 1.3% -2.63 [+2.3,0.92] Stubtotal (95% CI) 1100 1101 36.0% -2.05 [-2.74, -1.35] Heterogeneity. Tau" = 1.48; Chi" = 103 6.95 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001); P = 96% Heterogeneity. Tau" = 1.83; Chi" = 133 6.95 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001); P = 96%												
Yang 600 once per 3week 2021 6.73 2.12 5 8.46 1.7 5 1.5% -0.81 £ 2.13,051 Yang 600 once per 4week 2021 7.26 1.17 6 9.74 0.39 6 1.3% -2.63 £ 4.33, -0.92] Subtrotal (95% Ct) 1100 1101 36.0% -2.05 [2.74, -1.35] Heterogenetix, Tau ⁴ = 2.48; Ch ² = 704.39, df = 20 (P < 0.00001); P = 97% Total (95% Ct) 2371 2225 100.0% -1.94 [-2.30, -1.58] Heterogenetix, Tau ⁴ = 1.83; Ch ² = 1335.95, df = 59 (P < 0.00001); P = 96% Total (95% Ct) -10 -5 0 5 10 Estor overall effect Z = 10.50 (P < 0.00001) For the fect Z = 10.50 (P < 0.00001) For the fect Z = 10.50 (P < 0.00001) Subtract (P < 0.00001)												
Yang 60d once per 4week 2021 7.26 1.17 6 9.74 0.39 6 1.3% -2.63 [4.33, 0.92] Subtotal (95% Cl) 1100 1101 36.0% -2.05 [-2.74, -1.35] Heterogeneity: Tau" = 2.48; Chi" = 704.39, df = 20 (P < 0.00001); I" = 97%												
Stubtotal (95% Cl) 1100 1101 36.0% -2.05 [-2.74, -1.35] Heterogenety: Tau ² = 2.48; ChF = 704.39; dF = 20 (P < 0.00001); P = 97% Total (95% Cl) 2371 2225 100.0% -1.94 [-2.30, -1.58] Heterogenety: Tau ² = 1.83; ChF = 1335.95; dF = 59 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001) Feature concerned and Exercise Concerned and Exercise Concerned and Exercise Concerned and Exercise Concerned	Yang 60d once per 3week 2021	6.73								—		
Stubtotal (95% Cl) 1100 1101 36.0% -2.05 [-2.74, -1.35] Heterogenety: Tau ² = 2.48; ChF = 704.39; dF = 20 (P < 0.00001); P = 97% Total (95% Cl) 2371 2225 100.0% -1.94 [-2.30, -1.58] Heterogenety: Tau ² = 1.83; ChF = 1335.95; dF = 59 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001) Feature concerned and Exercise Concerned and Exercise Concerned and Exercise Concerned and Exercise Concerned	Yang 60d once per 4week 2021		1.17	6			6	1.3%	-2.63 [-4.33, -0.92]			
Test for overall effect Z = 5.76 (P < 0.00001) Total (95% Cl) 2371 2225 100.0% -1.94 [-2.30, -1.58] Heterogeneity: Tau ² = 1.83; Chi ² = 1335.95; df = 59 (P < 0.00001); P = 96% Test for overall effect Z = 10.50 (P < 0.00001) Test for overall effect Z = 10.50 (P < 0.00001) Est for overall effect Z = 10.50 (P < 0.00001)	Subtotal (95% CI)			1100			1101	36.0%		•		
Total (95% CI) 2371 2225 100.0% -1.94 [-2.30, -1.58] Heterogeneity, Tau ² = 1.83; Chi ² = 1.335.95, of = 59 (P < 0.00001); P = 96% Test for overall effect: Z = 10.50 (P < 0.00001) Estimation (P < 0.00001)				P < 0.0	10001); l ^a	²= 97%						
Helerogeneity: Tau ² = 1.83; Chi ² = 1335; 95; df = 59 (P < 0.00001); P = 96% Test for overall effect: Z = 10.50 (P < 0.00001) Ensure (example 10 - 5 0 5 10 Ensure (example 10 - 5 0 5 10)	Test for overall effect: Z = 5.76 (P	< 0.00001	1)									
Helerogeneity: Tau ² = 1.83; Chi ² = 1335; 95; df = 59 (P < 0.00001); P = 96% Test for overall effect: Z = 10.50 (P < 0.00001) Ensure (example 10 - 5 0 5 10 Ensure (example 10 - 5 0 5 10)	Total (05% CI)			2374			2225	100.0%	1041230 1501	•		
Test for overall effect: Z = 10.50 (P < 0.00001)		1006.06	df - FO		000013	17 - 0.6 f		100.0%	- 1.94 [-2.30, - 1.58]			
Test for overall energies (2 = 10.30 (r < 0.0001)) Favours (experimental) Favours (control) Favours (experimental) Favours (control)				(۲ < 0	00001);	1 = 90%	0					
	Test for overall effect. Z = 10.50 (F		JI) JK= 0.7		D 12 - 71					Favours (experimental) Favours (control)		

Figure 2. Forest plot showing the effects of photo-electric therapy for burn scars with different scar durations according to VSS, POSAS, thickness, and VAS [31–69]. Each trial is represented by a green point, and the size of the point is proportional to the information in that trial. The ends of the horizontal bars denote 95% confidence intervals (Cis). Black diamonds indicate the overall results of all trials. * In order to distinguish between the two Li's articles published in 2021, we have marked this one with an asterisk [43].

	Ехре	rimen	tal	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.5.1 Over 1 year									
lssler-Fisher 2021	2.9	1.4	167	3.6	1.6	167	9.4%	-0.70 [-1.02, -0.38]	
Li > 12m 2021*	2.31	0.54	11	3.91	0.75	11	6.1%	-1.60 [-2.15, -1.05]	←
Miletta 2021	0.95	0.33	22	1.35	0.48	22	10.8%	-0.40 [-0.64, -0.16]	
Subtotal (95% Cl)			200			200	26.2%	-0.85 [-1.41, -0.28]	
Heterogeneity: Tau ^z =	0.21; Ch	i ^z = 15	i.73, df	= 2 (P =	0.000	4); I ≃ =	87%		
Test for overall effect: 2	Z= 2.94	(P = 0)	003)						
1.5.2 6m-1y									
Joo 2022	0.27		88			88	13.3%	0.00 [-0.03, 0.03]	†
Kemp Bohan 2021	0.41	0.3	21		0.43	21	11.1%	-0.30 [-0.52, -0.08]	
Li > 6m 2021	2.46	0.77	43	2.57	0.63	43	9.8%	-0.11 [-0.41, 0.19]	
Subtotal (95% CI)			152			152		-0.12 [-0.32, 0.09]	
Heterogeneity: Tau ² =				2 (P = 0	0.03); [" = 72%)		
Test for overall effect: 2	2=1.12	(P = 0)	.26)						
1.5.3 Less than 6m									
Alsharnoubi 2018	0.34	0.09	15	0.52	0.17	15	12.8%	-0.18 [-0.28, -0.08]	—
Li 0 – 3m 2021	1.89	0.09	53		0.95	53	9.2%	-0.12 [-0.46, 0.22]	
Li 4 – 6m 2021	2.12		69		0.61	69	10.8%	-0.24 [-0.48, 0.00]	
Li ≤ 6m 2021*	2.99		17		0.79	17	6.8%	-1.11 [-1.60, -0.62]	←
Subtotal (95% CI)	2.55	0.00	154	4.1	0.75	154	39.6%	-0.34 [-0.61, -0.06]	
Heterogeneity: Tau ² =	0.06 [.] Ch	i ^z = 13		= 3 (P =	0.003				-
Test for overall effect: 2				0 ()	0.000	,,, ,	0 /0		
		(, 0.							
Total (95% Cl)			506			506	100.0%	-0.39 [-0.57, -0.20]	\bullet
Heterogeneity: Tau ² =	0.06; Ch	i ⁼ = 98	.82, df	= 9 (P <	0.000	01); ² =	= 91%	- / -	
Test for overall effect: 2			•						-1 -0.5 0 0.5 1
Test for subaroup diffe	erences:	Chi r =	: 6.40. d	df = 2 (P	= 0.04	4). I ^z = E	i8 8%		Favours (experimental) Favours (control)

Figure 3. Forest plot showing the effects of photo-electric therapy on the thickness of burn scars with different scar durations [35,43,45,48,53,58,63]. Each trial is represented by a green point, and the size of the point is proportional to the information in that trial. The ends of the horizontal bars denote 95% confidence intervals (Cis). Black diamonds give the overall results of all trials. * In order to distinguish between the two Li's articles published in 2021, we have marked this one with an asterisk [43].

3.3. Method for Burn Scarring

We also analyzed the effects of different photo-electric therapies for all periods of burn scars. The results showed significant differences between the methods (Figure 5) ($Chi^2 = 20.38$, df = 3 (p = 0.0001), I² = 85.3%). Overall, therapies that included IPL were found to work best.

For scarring less than one year, E-light (combined radiofrequency and IPL) offered significantly different improvement compared to other therapies. However, IPL was represented in only two studies of the 90 samples. Therefore, more studies on E-light should be performed (Figure 6). Although there was no significant difference between other therapies, it appears that CO_2 treatment was more effective than PDL.

		eriment			ontrol		1.0	Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.2.1 Over 1 year									
Douglas 2019	6.63	2.45	19	6.84	1.61	19	2.2%	-0.21 [-1.53, 1.11]	
El-Hoshy 2017	5.18	1.18	20	7.76	2.07	20	2.3%	-2.58 [-3.62, -1.54]	
Elrod 2020	4.88	1.73	17	7.65	2.12	17	2.2%	-2.77 [-4.07, -1.47]	
Gaida > 12m 2004	5.8	2.49	5	6.8	3.27	5	1.2%	-1.00 [-4.60, 2.60]	
					2.37		2.4%	-5.27 [-5.76, -4.78]	
Hultman 2013	5.16	1.92	147			147			
ssler-Fisher 2021	6	1.9	167	7.7	1.8	167	2.4%	-1.70 [-2.10, -1.30]	
<handelwal 2014<="" td=""><td>5.4</td><td>2.1</td><td>40</td><td>7.6</td><td>12.1</td><td>40</td><td>1.2%</td><td>-2.20 [-6.01, 1.61]</td><td></td></handelwal>	5.4	2.1	40	7.6	12.1	40	1.2%	-2.20 [-6.01, 1.61]	
Kono 2005	3.6	1.34	15	9.5	0.71	15	2.3%	-5.90 [-6.67, -5.13]	
_i > 12m 2021*	4.31	1.44	11	8.82	1.17	11	2.2%	-4.51 [-5.61, -3.41]	
Majid 2018	2	2.36	10	7	1.6	10	2.0%	-5.00 [-6.77, -3.23]	
Poetschke 2017	2.2	1.549	10		1.317	10	2.2%	-4.60 [-5.86, -3.34]	
		2					2.4%		
Tan > 12m 2021	7.7		55	9.2	1.8	55		-1.50 [-2.21, -0.79]	
Tawfic high density 2020	2.56	0.82	25	7.64	1.35	25	2.4%	-5.08 [-5.70, -4.46]	
Tawfic low density 2020	3.96	1.43	25	7.64	1.35	25	2.3%	-3.68 [-4.45, -2.91]	
Tawfic mediun density 2020	3.16	1.28	25	7.64	1.35	25	2.4%	-4.48 [-5.21, -3.75]	
Travis 2022	4.15	2.96	23	6.53	2.37	23	2.1%	-2.38 [-3.93, -0.83]	
Weshahy AFCL + GF 2020	3.5	1.5	15	7	3.5	15	1.9%	-3.50 [-5.43, -1.57]	
Weshahy AFCL only 2020	3	1.95	15	6.5	1.6	15	2.2%	-3.50 [-4.78, -2.22]	
	5	1.90	34	6.11	2.4	34	2.2%		
Zuccaro $> 12m 2018$	0	2		0.11	2.4			-1.11 [-2.16, -0.06]	
Subtotal (95% CI)			678			678	40.4%	-3.30 [-4.15, -2.46]	▼
Heterogeneity: Tau ² = 3.01; Chi ² =			(P < 0,	UOOO1);	1 = 949	ъ			the state of the second s
Test for overall effect: $Z = 7.68$ (P <	< 0.0000	1)							
1.2.2 6m-1y									
Gaida < 12m 2004	4.29	1.82	14	7.21	1.72	14	2.2%	-2.92 [-4.23, -1.61]	
Huang ACFL only 2021	7.8	0.6	12	13.8	0.6	12	2.4%	-6.00 [-6.48, -5.52]	
Huang AFCL + AFI 2021	4.5	0.4	12	13.5	0.7	12	2.4%	-9.00 [-9.46, -8.54]	
≺hedr Elight 2020	2.08	0.86	25	9.12	1.33	25	2.4%	-7.04 [-7.66, -6.42]	
Khedr Nd 2020	3.86	1.09	25	8.88	2.14	25	2.3%	-5.02 [-5.96, -4.08]	and a set of the set o
Li > 6m 2021	7.17	2.02	43	9.25	1.81	43	2.3%	-2.08 [-2.89, -1.27]	
Matuszczak 2021	4.04	2.85	25	9.2	3.06	25	2.0%	-5.16 [-6.80, -3.52]	
Tan 6–12m 2021	7.9	1.7	34	8.8	1.9	34	2.3%	-0.90 [-1.76, -0.04]	
Zuccaro 2021	4.85	0.53	20	8.62	0.54	20	2.4%	-3.77 [-4.10, -3.44]	
Zuccaro < 12m 2018	6.52	2.34	36	8.63	1.79	36	2.3%	-2.11 [-3.07, -1.15]	
Subtotal (95% CI)			246			246	23.0%	-4.41 [-6.07, -2.76]	
Heterogeneity: Tau ² = 6.92; Chi ² =	586.84,	df = 9 (F	P < 0.0	0001); l ²	= 98%				
Test for overall effect: Z = 5.22 (P <	< 0.0000	1)							
1.2.3 Less than 6m									
Elmelegy 2018	1.8	1.1	65	7.6	1.9	65	2.4%	-5.80 [-6.33, -5.27]	
_ei 3m – 6m 2015	8.2	1	25	12.2	1	25	2.4%	-4.00 [-4.55, -3.45]	
Lei 3w- 3m 2015	7	1.1	35	12.4	1.3	35	2.4%	-5.40 [-5.96, -4.84]	
Li 0 – 3m 2021	6.65	2.73	53	8.32	1.81	53	2.3%	-1.67 [-2.55, -0.79]	
_i 4 – 6m 2021	6.32	2.28	69	9.36	1.56	69	2.4%	-3.04 [-3.69, -2.39]	
LI PDL 2018	3.8	0.9	112	9.1	1.3	112	2.4%	-5.30 [-5.59, -5.01]	-
LI UFCL 2018	3.5	0.6	99	9.8	1.1	99	2.4%	-6.30 [-6.55, -6.05]	-
Li ≤ 6m 2021*	4.99	1.56	17	9.1	1.83	17	2.2%	-4.11 [-5.25, -2.97]	
Tan 1 – 3m 2021	7.7	2.2	50	9.2	2	50	2.3%	-1.50 [-2.32, -0.68]	
Tan 3–6m 2021	7.6	2.6	37	8.9	1.9	37	2.3%	-1.30 [-2.34, -0.26]	
Tan < 1m 2021	7.8	2.1	45	8.7	1.9	45	2.3%	-0.90 [-1.73, -0.07]	
Kie 2018	5	2.1	221	10.2	2	221	2.4%	-5.20 [-5.58, -4.82]	-
Yang 2022	4.11	0.81	169	7.93	1.4	169	2.4%	-3.82 [-4.06, -3.58]	
Yang 30d once per week 2021	5.54	3.34	4	7.12	3.34	4	0.9%	-1.58 [-6.21, 3.05]	
Yang 60d once per 2week 2021	5.64	3.81	5	7.09	3.81	5	0.9%	-1.45 [-6.17, 3.27]	
Yang 60d once per 3week 2021	6.73	2.12	5	8.46	1.7	5	1.7%	-1.73 [-4.11, 0.65]	
Yang 60d once per 4week 2021	7.26	1.17	6	9.74	0.39	6	2.3%	-2.48 [-3.47, -1.49]	
Subtotal (95% Cl)			1017			1017	36.6%	-3.51 [-4.29, -2.73]	-
Heterogeneity: Tau ² = 2.28; Chi ² =	542.92.	df = 16	(P < 0.)	00001);	I ² = 979	%			
Test for overall effect: Z = 8.84 (P <									
		1							
Fotal (95% CI)			1941			1941	100.0%	-3.62 [-4.19, -3.05]	
			1041			1241	.00.070	5.52 [-4.15, -5.05]	이 이상 방법에서 전화되었다. 이 집에 가지 않는 것이 없는 것이 없다.
Heterogeneity: Tau ² = 3.45; Chi ² =	1600.04	df - /	(D	00004	12 - 01	70/			

Figure 4. Forest plot showing the effects of photo-electric therapy using VSS for burn scars with different scar durations [31,33–36,38,39,41–43,45,46,50,52,54–57,59–62,64,65,67–69]. Each trial is represented by a green point, and the size of the point is proportional to the information in that trial. The ends of the horizontal bars denote 95% confidence intervals (Cis). Black diamonds indicate the overall results of all trials. * In order to distinguish between the two Li's articles published in 2021, we have marked this one with an asterisk [43].

	Ехре	erimental			ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
2.2.1 CO2									
Douglas 2019	6.63	2.45	19	6.84	1.61	19	1.8%	-0.21 [-1.53, 1.11]	
El-Hoshy 2017	5.18	1.18	20	7.76	2.07	20	1.9%	-2.58 [-3.62, -1.54]	
Elrod 2020	4.88	1.73	17	7.65	2.12	17	1.8%	-2.77 [-4.07, -1.47]	
Huang ACFL only 2021	7.8	0.6	12	13.8	0.6	12	2.0%	-6.00 [-6.48, -5.52]	_
Huang AFCL + AFI 2021	4.5 5.16	0.4 1.92	12	13.5 10.43	0.7 2.37	12 147	2.1% 2.0%	-9.00 [-9.46, -8.54]	_
Hultman 2013 Issler-Fisher 2021	0.10		167	7.7		167	2.0%	-5.27 [-5.76, -4.78] -1.70 [-2.10, -1.30]	_
Khandelwal 2014	5.4	2.1	40	7.6	1.8 12.1	40	0.9%	-2.20 [-6.01, 1.61]	
Lei 3m – 6m 2015	8.2	1	25	12.2	12.1	25	2.0%	-4.00 [-4.55, -3.45]	_
Lei 3w – 3m 2015	7	1.1	35	12.4	1.3	35	2.0%	-5.40 [-5.96, -4.84]	_
Li UFCL 2018	3.5	0.6	99	9.8	1.1	99	2.1%	-6.30 [-6.55, -6.05]	-
Li ≤ 6m 2021*	4.99	1.56	17	9.1	1.83	17	1.9%	-4.11 [-5.25, -2.97]	
Li > 12m 2021*	4.31	1.44	11	8.82	1.17	11	1.9%	-4.51 [-5.61, -3.41]	
Majid 2018	2	2.36	10	7	1.6	10	1.6%	-5.00 [-6.77, -3.23]	
Matuszczak 2021	4.04	2.85	25	9.2	3.06	25	1.7%	-5.16 [-6.80, -3.52]	
Poetschke 2017	2.2	1.549	10		1.317	10	1.8%	-4.60 [-5.86, -3.34]	
Tan 1 – 3m 2021	7.8	2.1	45	8.7	1.9	45	2.0%	-0.90 [-1.73, -0.07]	
Tan 3–6m 2021	7.7	2	55	9.2	1.8	55	2.0%	-1.50 [-2.21, -0.79]	_
Tan 6 – 12m 2021	7.7	2.2	50	9.2	2	50	2.0%	-1.50 [-2.32, -0.68]	
Tan < 1m 2021	7.9	1.7	34	8.8	1.9	34	2.0%	-0.90 [-1.76, -0.04]	
Tan > 12m 2021	7.6	2.6	37	8.9	1.9	37	1.9%	-1.30 [-2.34, -0.26]	
Tawfic high density 2020	2.56	0.82	25	7.64	1.35	25	2.0%	-5.08 [-5.70, -4.46]	_
Tawfic low density 2020	3.96	1.43	25	7.64	1.35	25	2.0%	-3.68 [-4.45, -2.91]	
Tawfic mediun density 2020	3.16	1.28	25	7.64	1.35	25	2.0%	-4.48 [-5.21, -3.75]	
Travis 2022	4.15	2.96	23	6.53	2.37	23	1.7%	-2.38 [-3.93, -0.83]	
Weshahy AFCL + GF 2020	3.5	1.5	15	7	3.5	15	1.6%	-3.50 [-5.43, -1.57]	
Weshahy AFCL only 2020	3	1.95	15	6.5	1.6	15	1.8%	-3.50 [-4.78, -2.22]	
Xie 2018	5		221	10.2	2	221	2.1%	-5.20 [-5.58, -4.82]	_
Yang 2022	4.11		169	7.93	1.4	169	2.1%	-3.82 [-4.06, -3.58]	
Zuccaro 2021	4.85	0.53	20	8.62	0.54	20	2.1%	-3.77 [-4.10, -3.44]	
Zuccaro < 12m 2018 Zuccaro > 12m 2018	6.52 5	2.34 2	36	8.63 6.11	1.79 2.4	36	1.9% 1.9%	-2.11 [-3.07, -1.15]	
Subtotal (95% Cl)	5		34 495	0.11	2.4	34 1495	60.8%	-1.11 [-2.16, -0.06] - 3.59 [-4.29, -2.88]	•
Heterogeneity: Tau ² = 3.83; Chi ² =	- 1331 03			00001)	1 ² - 98		00.070	-5.55 [-4.25, -2.00]	•
Test for overall effect: $Z = 9.97$ (P					1 - 50	,,0			
	0.0000	''							
2.2.2 PDL									
Elrod 2020	4.88	1.73	17	7.65	2.12	17	1.8%	-2.77 [-4.07, -1.47]	
Hultman 2013	5.16			10.43	2.37	147	2.0%	-5.27 [-5.76, -4.78]	-
Kono 2005	3.6	1.34	15	9.5	0.71	15	2.0%	-5.90 [-6.67, -5.13]	
Li 0 – 3m 2021	3.8	0.9	112	9.1	1.3	112	2.1%	-5.30 [-5.59, -5.01]	-
Li 4–6m 2021	7.17	2.02	43	9.25	1.81	43	2.0%	-2.08 [-2.89, -1.27]	
Li PDL 2018	6.65	2.73	53	8.32	1.81	53	2.0%	-1.67 [-2.55, -0.79]	
Li > 6m 2021	6.32	2.28	69	9.36	1.56	69	2.0%	-3.04 [-3.69, -2.39]	
Matuszczak 2021	4.04	2.85	25	9.2	3.06	25	1.7%	-5.16 [-6.80, -3.52]	
Xie 2018	5	2.1	221	10.2	2	221	2.1%	-5.20 [-5.58, -4.82]	-
Yang 30d once per week 2021	5.54	3.34	4	7.12	3.34	4	0.7%	-1.58 [-6.21, 3.05]	
Yang 60d once per 2week 2021	5.64	3.81	5	7.09	3.81	5	0.7%	-1.45 [-6.17, 3.27]	
Yang 60d once per 3week 2021	6.73	2.12	5	8.46	1.7	5	1.4%	-1.73 [-4.11, 0.65]	
Yang 60d once per 4week 2021	7.26	1.17	6	9.74	0.39	6	1.9%	-2.48 [-3.47, -1.49]	
Zuccaro 2021	4.85	0.53	20	8.62	0.54	20	2.1%	-3.77 [-4.10, -3.44]	
Zuccaro < 12m 2018	6.52	2.34	36	8.63	1.79	36	1.9%	-2.11 [-3.07, -1.15]	
Zuccaro $> 12m 2018$	5	2	34	6.11	2.4	34	1.9%	-1.11 [-2.16, -0.06]	
Subtotal (95% CI)	- 766 55		812	100043-1	Z - 040	812 «	28.3%	-3.40 [-4.14, -2.66]	•
Heterogeneity: Tau ² = 1.83; Chi ² = Test for overall effect: Z = 9.00 (P			S U.(10001),1	- 949	0			
	. 0.0000	·)							
2.2.4 LLLT									
Gaida < 12m 2004	4.29	1.82	14	7.21	1.72	14	1.8%	-2.92 [-4.23, -1.61]	
Gaida > 12m 2004	4.29	2.49	5	6.8	3.27	5	1.8%	-1.00 [-4.60, 2.60]	
Khedr Nd 2020	3.86	1.09	25		2.14	25	1.0%	-5.02 [-5.96, -4.08]	
Subtotal (95% Cl)	5.00		44	0.00	2.1.4	44	4.7%	-3.45 [-5.46, -1.45]	
Heterogeneity: Tau ² = 2.24; Chi ² =	= 9.59. df	= 2 (P = 0		; I ² = 799	ж	.,		,	
Test for overall effect: Z = 3.37 (P			-/						
2.2.5 IPL									
Elmelegy 2018	1.8	1.1	65	7.6	1.9	65	2.0%	-5.80 [-6.33, -5.27]	_
Hultman 2013	5.16	1.92		10.43	2.37	147	2.0%	-5.27 [-5.76, -4.78]	_
Khedr Elight 2020	2.08	0.86	25	9.12	1.33	25	2.0%	-7.04 [-7.66, -6.42]	_
Subtotal (95% CI)			237			237	6.1%	-6.02 [-7.00, -5.04]	-
Heterogeneity: Tau ² = 0.67; Chi ² =			0.000	01); I ^z = 9	90%				
Test for overall effect: $Z = 12.01$ (F	o < 0.000	J1)							
Tatal (05% CI)		~	500			2500	400.0%	2671440 247	
Total (95% CI)	1700		588	00004	17 07		100.0%	-3.67 [-4.16, -3.17]	
Heterogeneity: Tau ² = 2.99; Chi ² =			۲ < 0	.00001);	r= 97	%			-10 -5 0 5 10
Test for overall effect: Z = 14.65 (F				0004	0.5.5	04			Favours (experimental) Favours (control)
est for subaroup differences: Ch	ni = 20.38	3. df = 3 (F	P = 0.	0001). I ^z	= 85.3	1%			i avoura (experimentar) i avoura (control)

Figure 5. Forest plot showing the effects of different photo-electric therapies for burn scars, using VSS [31,33–36,38,39,41–43,45,46,50,52,54–57,59–62,64,65,67–69]. Each trial is represented by a green point, and the size of the point is proportional to the information in that trial. The ends of the horizontal bars denote 95% confidence intervals (Cis). Black diamonds give the overall results of all trials. * In order to distinguish between the two Li's articles published in 2021, we have marked this one with an asterisk [43].

study or Subgroup	Mean	eriment SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
.1.1 CO2	pare? 1	- 60° -	0.000		- Andrew State	Let 1 - S	2000 C		
e 2008	55.03	18.19	21	70.03	17.49	21	3.1%	-0.82 [-1.46, -0.19]	the and the second s
luang ACFL only 2021	7.8	0.6	12	13.8	0.6	12	1.5%	-9.66 [-12.75, -6.56]	
luang AFCL + AFI 2021	4.5	0.4	12	13.5	0.7	12	0.8%	-15.24 [-20.03, -10.46]	←
emp Bohan 2021	0.41	0.3	21	0.71	0.43	21	3.1%	-0.79 [-1.42, -0.16]	
ei 3m – 6m 2015	8.2	1	25	12.2	1	25	2.9%	-3.94 [-4.91, -2.96]	
.ei 3w– 3m 2015	7	1.1	35	12.4	1.3	35	2.9%	-4.43 [-5.32, -3.55]	
iu 2022	26.48	6.6	23		4.56	23	3.1%	-1.14 [-1.76, -0.51]	
J UFCL 2018	3.5	0.6	99	9.8	1.1	99	3.0%	-7.08 [-7.84, -6.33]	
i ≤ 6m 2021*	4.99	1.56	17	9.1	1.83	17	2.9%	-2.36 [-3.26, -1.46]	—
1atuszczak 2021	4.04	2.85	25	9.2	3.06	25	3.1%	-1.72 [-2.37, -1.06]	-
an 1 – 3m 2021	7.8	2.1	45	8.7	1.9	45	3.2%	-0.45 [-0.86, -0.03]	-
an 3 – 6m 2021	7.7	2	55	9.2	1.8	55	3.2%	-0.78 [-1.17, -0.39]	-
an 6 – 12m 2021	7.7	2.2	50	9.2	2	50	3.2%	-0.71 [-1.11, -0.30]	
an < 1m 2021	7.9	1.7	34	8.8	1.9	34	3.1%	-0.49 [-0.98, -0.01]	-
ie 2018	5	2.1	221	10.2	2	221	3.2%	-2.53 [-2.78, -2.28]	
ang 2022	4.11	0.81	169	7.93	1.4	169	3.2%	-3.33 [-3.66, -3.00]	
Luccaro 2021	4.85	0.53	20	8.62	0.54	20	2.4%	-6.91 [-8.62, -5.20]	
Luccaro < 12m 2018	6.52	2.34	36	8.63	1.79	36	3.1%	-1.00 [-1.49, -0.51]	
ubtotal (95% Cl)	0.52	2.34	920	0.05	1.75	920	50.8%	-2.80 [-3.57, -2.02]	•
leterogeneity: Tau ² = 2.52; Chi ² =	- 607 00	df = 1.7		100011	= 070		50.070	-2.00[-3.37, -2.02]	
			(F = 0.1	50001),	1 - 9/ 7	0			
est for overall effect: Z = 7.04 (P	< 0.0000	0							
.1.2 PDL									
	2.0	0.0	110	0.1	1 2	110	210	4701504 4041	
i 0 – 3m 2021	3.8	0.9	112	9.1	1.3	112	3.1%	-4.72 [-5.24, -4.21]	_
i 4 – 6m 2021	7.17	2.02	43	9.25	1.81	43	3.1%	-1.07 [-1.53, -0.62]	
i PDL 2018	6.65	2.73	53	8.32	1.81	53	3.2%	-0.72 [-1.11, -0.32]	
latuszczak 2021	4.04	2.85	25	9.2	3.06	25	3.1%	-1.72 [-2.37, -1.06]	
ie 2018	5	2.1	221	10.2	2	221	3.2%	-2.53 [-2.78, -2.28]	
ang 30d once per week 2021	5.54	3.34	4	7.12	3.34	4	2.6%	-0.41 [-1.83, 1.00]	
ang 60d once per 2week 2021	5.64	3.81	5	7.09	3.81	5	2.7%	-0.34 [-1.60, 0.91]	
ang 60d once per 3week 2021	6.73	2.12	5	8.46	1.7	5	2.7%	-0.81 [-2.13, 0.51]	
ang 60d once per 4week 2021	7.26	1.17	6	9.74	0.39	6	2.4%	-2.63 [-4.33, -0.92]	
uccaro 2021	4.85	0.53	20	8.62	0.54	20	2.4%	-6.91 [-8.62, -5.20]	
uccaro < 12m 2018	6.52	2.34	36	8.63	1.79	36	3.1%	-1.00 [-1.49, -0.51]	
ubtotal (95% Cl)			530			530	31.5%	-2.02 [-2.90, -1.13]	•
leterogeneity: Tau² = 1.98; Chi² =			(P < 0.0	00001);	I ² = 96%	þ			
est for overall effect: $Z = 4.46$ (P	< 0.0000	1)							
.1.3 E-light									
Imelegy 2018	1.8	1.1	65	7.6	1.9	65	3.1%	-3.71 [-4.29, -3.14]	
hedr Elight 2020	2.08	0.86	25	9.12	1.33	25	2.6%	-6.19 [-7.57, -4.81]	
Subtotal (95% CI)			90			90	5.7%	-4.87 [-7.29, -2.45]	-
leterogeneity: Tau² = 2.77; Chi² =			= 0.001	1); I ⁼ = 9	1%				2013년 - 1914년 - 1917년 1월 1917년 1월 1918년 1월 1918년 1917년 - 1919년 - 1919년 1월 1918년 1월 1918년 1919년 - 1918년 - 1918년 1월 1918년
est for overall effect: $Z = 3.95$ (P	< 0.0001)							
.1.4 LLLT									
Isharnoubi 2018	0.34	0.09	15	0.52	0.17	15	3.0%	-1.29 [-2.08, -0.49]	
bid 2017	4.44	4.21	24	8.55	2.65	25	3.1%	-1.16 [-1.76, -0.55]	
aida < 12m 2004	4.29	1.82	14	7.21	1.72	14	2.9%	-1.60 [-2.47, -0.73]	
hedr Nd 2020 ubtotal (95% Cl)	3.86	1.09	25 78	8.88	2.14	25 79	3.0% 12.0 %	-2.91 [-3.72, -2.10] - 1.72 [-2.50, -0.94]	•
leterogeneity: Tau ^z = 0.48; Chi ^z = est for overall effect: Z = 4.31 (P			= 0.000	6); I ² = 7	6%				
otal (95% Cl)			1618			1619	100.0%	-2.51 [-3.02, -2.00]	•
leterogeneity: Tau ² = 2.11; Chi ² =	= 931.66.	df = 34	(P < 0.1)	00001):	² = 96%				
est for overall effect: Z = 9.63 (P			1						-10 -5 0 5 10
				4). I [≈] = 8	1 000				Favours (experimental) Favours (control)

Figure 6. Forest plot showing the effects of different photo-electric therapies for burn scars within 1 year. Each trial is represented by a green point, and the size of the point is proportional to the information in that trial. The ends of the horizontal bars denote 95% confidence intervals (CIs). Black diamonds give the overall results of all trials. * In order to distinguish between the two Li's articles published in 2021, we have marked this one with an asterisk [43].

3.4. Publication Bias

Our assessment showed no evidence of significant publication bias based on formal statistical tests (Egger's test, p = 0.056 > 0.05).

4. Discussion

In this study, we found that treatments for scarring over six months and one year have significant improvement differences in general presentation compared to other periods of scarring. The formation of scarring can be divided into three stages: inflammation, proliferation, and remodeling. During the first few days after an injury, corresponding to the inflammation stage, a variety of chemokines and vessel active mediators are produced at the site of the injury [70]. Then, in the proliferation stage, vessel active mediators, such as vascular endothelial growth factor (VEGF), from the previous stage induce microvascular scar tissue, which leads to scar proliferation [71–73]. The degree of microvascular density and scar hyperplasia are positively correlated [74]. Therefore, theoretically, intervention in this period can reduce angiogenesis, which can help relieve pruritus, contracture scars, and prevent scar growth and dysfunction. Histological analysis showed that the density of blood vessels in scar tissue increases significantly starting at one month after wound healing [74]. Then, hypertrophic scars generally develop in 2~6 months [27]. However, the results vary greatly between individuals due to different factors. Notably, burn scarring, the time of healing, and remodeling can be prolonged [30], so the best time for intervention in burn scarring is within one year, as shown by our results; interventions may also need to be personalized. Poetschke, J et al. [28] published a similar review on the treatment of immature scarring and concluded that a treatment algorithm should be formulated according to each patient's needs. In conflict with our results, Brewin, M. P et al. [27] proposed that the treatment of PDL should begin before six months, when the scarring remains immature. This difference depends on the definition of immature scarring. As we mentioned, the duration of immature scarring varies greatly between individuals, making it difficult to clearly determine the ideal intervention time. Thus, the best way to deliver treatment is to follow-up with the patient as early as possible and avoid starting treatment too late. Treatment within one year is a good choice based on our results. Lastly, in the remodeling phase, the scar no longer presents redness, and for a hypertrophic or keloid scar, the scar may continue to thicken. This agrees with our outcome that in terms of thickness, photo-electric therapy corresponds to significant differences in improvement of the scar over one year.

In our study, treatment with the addition of IPL offered better improvements than other devices, especially for burn scars treated within one year. IPL therapy is non-invasive, non-surgical, and preliminarily filtered, forming an intense light with a wavelength of 400 to 1200 nm. IPL is not a laser but has similar characteristics to a laser [72]. Through the function of selective photothermolysis, light energy is absorbed by chromophore oxyhemoglobin, which is abundant in the blood vessels, causing photocoagulation of the vascular endothelium. This chromophore can also be absorbed by melanin in the epidermis. Thus, after the application of IPL, melanosomes in the epidermal melasma quickly move to the surface of the skin, undergo desquamation, and take the form of tiny crusts. Li. N et al. [75] used IPL to treat 35 Chinese patients who had a history of skin burns within the past year. The results showed that IPL is effective and safe in Chinese patients with postburn hyperpigmentation and telangiectasia. Meanwhile, as the maximum absorption by collagen occurs in the visible and near-infrared spectra [76], the light can also be absorbed by collagen. It was further confirmed that, with IPL, the activity of fibroblasts is increased, causing upregulation of type-I and type-III collagens at the mRNA and protein levels and rearranging elastin fibers both in vitro and in vivo [77,78]. However, we did not find a convincing systematic review that evaluated the effectiveness of IPL. In the systematic review of Vrijman, C et al. [76], the authors did not find any evidence for the efficacy of IPL therapy, as no study met the inclusion criteria. Zuccaro, Jv [24] found only one study about IPL, which reported mild-to-significant improvement in scarring.

With the development of technology, filtering narrow-spectrum intense pulsed light (DPL) of 500–600 nm through the spectrum at both ends can make treatment energy more concentrated; when the spot is large and uniform, the energy is lower and can more effectively protect normal skin tissue around the scar. This method offers the precision of a laser and the safety of strong pulsed light, greatly improving the curative effects. DPL still contains the absorption peak of hemoglobin, reduces the absorption of light by other tissue, and can use higher energy to block blood vessels; DPL can also inhibit angiogenesis, is more specific than IPL, and leads to less pain than PDL [72,79]. Zhang et al. [79] used DPL to treat 90 patients with scars after 3 weeks but within 1 year. After treatment for 3 months,

the pruritus of scars was obviously alleviated. The degree of microvascular regeneration was related to the formation of erythema in the scar, which, in turn, became taller and harder, as well as the level of the hypertrophy of the scar [80]. As a result, we suggest that once the scar heals and appears red, photo-electric therapy that targets neovascularization should be started.

At the same time, the effectiveness of other methods cannot be ignored. Our study still showed a great effect of CO₂AFL, PDL, LLLT, and RF on scar appearance. The CO₂AFL can create 3D microthermal damage zones, thereby decreasing wound repair time and adverse reactions. Additionally, the use of fractional carbon dioxide laser treatment for hypertrophic scars can promote a decrease in type I collagen in scar tissue and an increase in type III collagen, which is closer to the collagen structure of normal skin tissue [81]. This treatment can also cause damage to blood vessels, producing scar ischemia and releasing collagenase to break down collagen, while the thermal effect of lasers can also stimulate collagen synthesis and remodeling, which helps to promote collagen remodeling as well as improve the appearance of scars [50]. A recent study compared the effects of starting CO_2AFL treatment at multiple times after injury. One month after the last treatment, the results showed that CO₂AFL was more effective for scars after more than 12 months in terms of height and pliability. However, for hardness and redness, scars at 1–3 months presented better results than other groups. The authors suggested that the ideal time point for the initiation of early fractional laser treatment could be within 1 month after injury [38]. However, there are some common side effects of CO2AFL, including erythema, seepage, bleeding, swelling, pigmentation, and deterioration of scarring [38,82]. Lower density with moderate laser energy for treating scars was proposed to avoid such problems.

PDL (pulsed dye laser) is the most widely used and effective type of laser for preventing early scarring [83]. According to the principle of selective photothermolysis, hemoglobin has two absorption peaks at 542 and 578 nm. Therefore, a laser at 585 nm will have a noticeable effect on eliminating blood vessels. Meanwhile, through the function of photothermolysis, collagen fibers are heated, and the disulfide bonds are broken, enabling them to be catabolized. In this way, collagen over-deposition can be prevented, stimulating collagen remodeling and allowing for the structure of scar epithelial tissue to be reconstructed [46,84]. However, the efficacy of PDL is limited by the thickness of the lesion. PDL penetrates to a depth of approximately 1.2 mm [85]. The most common side effect of PDL is postdelivery purpura, which persist for up to 7–10 days [41]. When the PDL energy is too high, pigment loss can easily occur [27]. Thus, to treat deeper lesions and reduce the side effects at the same time, more methods for combining other treatments with PDL need to be developed. Recently, Naoaki Rikihisa et al. [86] found that intravenous preadministration of carbonyl hemoglobin vesicles (CO-HbVs) followed by the application of vascular selective laser irradiation to the blood vessels of rabbit pinna reduced thermal damage to the perivascular tissue and partially enhanced vascular damage. In combination with Nd:YAG, PDL first changes hemoglobin into methemoglobin, which can absorb more energy from the Nd:YAG laser and thus penetrate more deeply [84].

LLLT treats scars in a different way by acting on the skin through photobiomodulation (PBM), which is an efficient and safe therapeutic modality for postburn scars. LLLT was found to suppress the viability of fibroblasts, inhibit the proliferation and formation of collagen in skin, and increase apoptosis of fibroblasts through mitochondria [87,88]. LLLT can also improve macrophage migration and phagocytosis independently of TGF- β signaling [89]. At present, LLLT is known to cause no side effects, which is a great advantage in early scar treatment [48]. It is known with certainty that LLLT promotes beneficial effects in the early stages of burn injury. However, we still need more basic and clinical studies to understand the relevant mechanisms and direct the best parameters for each type of burn, each type of skin, and each stage of scarring.

Finally, the mechanism underlying the RF stimulation of collagen fiber remodeling is likely protein denaturation caused by the effects of heat followed by the stimulation of collagen synthesis due to the increased expression of heat shock proteins [90]. With the development of fractional technology, in 2010, fractional microplasma radiofrequency technology (FMRT) was developed and initially used for the treatment of facial scars and rhytids [91]. Pinheiro et al. [92] compared the histological examination of postburn hypertrophic scar tissue treated with RF. The results showed that the treated area featured collagen fiber density in the papillary and reticular dermis similar to that of normal skin. This density was significantly greater in the area with no RF treatment [93]. However, the thermal effects of radiofrequency occur in the deeper layers of the skin, so short-term irritation, edema, and even burns can occur [94]. Additionally, numbness and sensory dullness can occur when thermal coagulation leads to demyelination of sensory nerves [95], so more experienced operators are needed for treatment.

5. Conclusions

In conclusion, this study indicated that treatment starting between six months and one year after injury had better outcomes in terms of the general presentation of scarring. Meanwhile, using IPL for burn scarring treatment seems to have better effects than other methods, especially for scarring within one year. We suggest using IPL and, especially, DPL for the treatment of early burn scarring. Notably, the scientific evidence in this area remains insufficient. We need more clinical trials of higher quality and less heterogeneity to confirm our results.

6. Limitations

There are still some limitations to this study. First, the majority of studies we included used pretreatment controls. Most burn scars improve over time, but concurrent control experiments in this area are extremely scarce. There is also a lack of higher-quality clinical trials, such as RCTs, and an inability to apply a double-blinded method for laser therapy. Meanwhile, some studies featured very short follow-ups. Significant heterogeneity was also observed among the studies included in this systematic review, including in the parameters, the application of different treatments, and the lack of general assessments evaluating burn scars. As a result, more well-performed, larger RCTs need to be carried out. The various evaluation criteria (POSAS for the patient and observer, VSS, etc.) also need to be standardized to further verify our results.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ebj4020013/s1, Figure S1: Forest plot showing the effects of photo-electric therapy for burn scars according to VSS, POSAS, thickness, and VAS for the group with scarring for over one year and the group with scarring between six months and one year; File S1: the PRISMA-2020-Checklist [96–98].

Author Contributions: Conceptualization, M.Y.; methodology, Y.B. and Y.Z.; validation, Y.B., Y.Z. and W.N.; data curation, Y.B., Y.Z. and W.N.; data analysis, Y.B. and Y.Z.; writing—original draft preparation, Y.B.; writing—review and editing, Y.B.; Y.Z. and M.Y.; project administration, M.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by Local High Level University Construction Program at Shanghai Jiao Tong University School of medicine.

Data Availability Statement: The original data are included in the article. Further information can be obtained from the corresponding author.

Acknowledgments: We would like to thank all the scientists who provided us with the detailed experimental data and Nicolas G. who helped us significantly.

Conflicts of Interest: The authors state no conflict of interest.

References

- 1. Peck, M.D.; Kruger, G.E.; Van Der Merwe, A.E.; Godakumbura, W.; Ahuja, R.B. Burns and fires from non-electric domestic appliances in low and middle income countries Part I. The scope of the problem. *Burns* **2008**, *34*, 303–311. [CrossRef] [PubMed]
- Forjuoh, S.N. Burns in low- and middle-income countries: A review of available literature on descriptive epidemiology, risk factors, treatment, and prevention. *Burns* 2006, 32, 529–537. [CrossRef] [PubMed]
- 3. Arno, A.I.; Gauglitz, G.G.; Barret, J.P.; Jeschke, M.G. Up-to-date approach to manage keloids and hypertrophic scars: A useful guide. *Burns* **2014**, *40*, 1255–1266. [CrossRef] [PubMed]
- 4. Bloemen, M.C.; van der Veer, W.M.; Ulrich, M.M.; van Zuijlen, P.P.; Niessen, F.B.; Middelkoop, E. Prevention and curative management of hypertrophic scar formation. *Burns* **2009**, *35*, 463–475. [CrossRef]
- Oosterwijk, A.M.; Mouton, L.J.; Schouten, H.; Disseldorp, L.M.; van der Schans, C.P.; Nieuwenhuis, M.K. Prevalence of scar contractures after burn: A systematic review. *Burns* 2017, 43, 41–49. [CrossRef]
- 6. Zuber, T.J.; DeWitt, D.E. Earlobe keloids. Am. Fam. Physician 1994, 49, 1835–1841.
- Hatamipour, E.; Mehrabi, S.; Hatamipour, M.; Ghafarian Shirazi, H.R. Effects of combined intralesional 5-Fluorouracil and topical silicone in prevention of keloids: A double blind randomized clinical trial study. *Acta Med. Iran.* 2011, 49, 127–130.
- Hassel, J.C.; Loser, C.; Koenen, W.; Kreuter, A.; Hassel, A.J. Promising results from a pilot study on compression treatment of ear keloids. J. Cutan. Med. Surg. 2011, 15, 130–136. [CrossRef]
- Nast, A.; Eming, S.; Fluhr, J.; Fritz, K.; Gauglitz, G.; Hohenleutner, S.; Panizzon, R.G.; Sebastian, G.; Sporbeck, B.; Koller, J.; et al. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). J. Dtsch. Dermatol. Ges. 2012, 10, 747–762. [CrossRef]
- 10. Robles, D.T.; Berg, D. Abnormal wound healing: Keloids. Clin. Dermatol. 2007, 25, 26–32. [CrossRef]
- 11. Poochareon, V.N.; Berman, B. New therapies for the management of keloids. J. Craniofac. Surg. 2003, 14, 654–657. [CrossRef]
- 12. Gold, M.H.; Berman, B.; Clementoni, M.T.; Gauglitz, G.G.; Nahai, F.; Murcia, C. Updated international clinical recommendations on scar management: Part 1—Evaluating the evidence. *Dermatol. Surg.* **2014**, *40*, 817–824.
- Gold, M.H.; McGuire, M.; Mustoe, T.A.; Pusic, A.; Sachdev, M.; Waibel, J.; Murcia, C.; International Advisory Panel on Scar, M. Updated international clinical recommendations on scar management: Part 2—Algorithms for scar prevention and treatment. *Dermatol. Surg.* 2014, 40, 825–831. [CrossRef]
- 14. Ahuja, R.B.; Chatterjee, P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. *Burns* 2014, 40, 583–588. [CrossRef]
- 15. Grisolia, G.A.; Danti, D.A.; Santoro, S.; Panozzo, G.; Bonini, G.; Pampaloni, A. Injection therapy with triamcinolone hexacetonide in the treatment of burn scars in infancy: Results of 44 cases. *Burns* **1983**, *10*, 131–134. [CrossRef]
- Wang, X.Q.; Liu, Y.K.; Qing, C.; Lu, S.L. A review of the effectiveness of antimitotic drug injections for hypertrophic scars and keloids. *Ann. Plast. Surg.* 2009, 63, 688–692.
- Trisliana Perdanasari, A.; Torresetti, M.; Grassetti, L.; Nicoli, F.; Zhang, Y.X.; Dashti, T.; Di Benedetto, G.; Lazzeri, D. Intralesional injection treatment of hypertrophic scars and keloids: A systematic review regarding outcomes. *Burn. Trauma* 2015, *3*, 14. [CrossRef]
- 18. Fredman, R.; Tenenhaus, M. Cushing's syndrome after intralesional triamcinolone acetonide: A systematic review of the literature and multinational survey. *Burns* 2013, *39*, 549–557. [CrossRef]
- 19. Ragoowansi, R.; Cornes, P.G.; Moss, A.L.; Glees, J.P. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. *Plast. Reconstr. Surg.* **2003**, *111*, 1853–1859. [CrossRef]
- Cho, Y.S.; Jeon, J.H.; Hong, A.; Yang, H.T.; Yim, H.; Cho, Y.S.; Kim, D.H.; Hur, J.; Kim, J.H.; Chun, W.; et al. The effect of burn rehabilitation massage therapy on hypertrophic scar after burn: A randomized controlled trial. *Burns* 2014, 40, 1513–1520. [CrossRef]
- 21. Willows, B.M.; Ilyas, M.; Sharma, A. Laser in the management of burn scars. Burns 2017, 43, 1379–1389. [CrossRef] [PubMed]
- Choi, K.J.; Williams, E.A.; Pham, C.H.; Collier, Z.J.; Dang, J.; Yenikomshian, H.A.; Gillenwater, T.J. Fractional CO₂ laser treatment for burn scar improvement: A systematic review and meta-analysis. *Burns* 2021, 47, 259–269. [CrossRef] [PubMed]
- Mahar, P.D.; Spinks, A.B.; Cleland, H.; Bekhor, P.; Waibel, J.S.; Lo, C.; Goodman, G. Improvement of Burn Scars Treated with Fractional Ablative CO₂ Lasers-A Systematic Review and Meta-analysis Using the Vancouver Scar Scale. *J. Burn Care Res.* 2021, 42, 200–206. [CrossRef] [PubMed]
- 24. Zuccaro, J.; Ziolkowski, N.; Fish, J. A Systematic Review of the Effectiveness of Laser Therapy for Hypertrophic Burn Scars. *Clin. Plast. Surg.* **2017**, *44*, 767–779. [CrossRef] [PubMed]
- Kent, R.A.; Shupp, J.; Fernandez, S.; Prindeze, N.; DeKlotz, C.M.C. Effectiveness of Early Laser Treatment in Surgical Scar Minimization: A Systematic Review and Meta-analysis. *Dermatol. Surg.* 2020, 46, 402–410. [CrossRef]
- 26. Behrouz-Pirnia, A.; Liu, H.; Peternel, S.; Dervishi, G.; Labeit, A.; Peinemann, F. Early laser intervention to reduce scar formation in wound healing by primary intention: A systematic review. *J. Plast. Reconstr. Aesthet. Surg.* **2020**, *73*, 528–536. [CrossRef]
- 27. Brewin, M.P.; Lister, T.S. Prevention or treatment of hypertrophic burn scarring: A review of when and how to treat with the pulsed dye laser. *Burns* **2014**, *40*, 797–804. [CrossRef]
- Poetschke, J.; Gauglitz, G.G. Treatment of Immature Scars: Evidence-Based Techniques and Treatments. In *Textbook on Scar* Management: State of the Art Management and Emerging Technologies; Springer: Cham, Switzerland, 2020.

- Santer, M.; Kloppenburg, M.; Gottfried, T.A.-O.; Runge, A.; Schmutzhard, J.; Vorbach, S.M.; Mangesius, J.A.-O.; Riedl, D.A.-O.; Mangesius, S.A.-O.; Widmann, G.; et al. Current Applications of Artificial Intelligence to Classify Cervical Lymph Nodes in Patients with Head and Neck Squamous Cell Carcinoma—A Systematic Review. *Cancers* 2022, 14, 5397. [CrossRef]
- Chinese Association of Plastics; Aesthetics Scar Medicine Branch. National expert consensus on early management of scars (2020 version). *Zhonghua Shao Shang Za Zhi* 2021, 37, 113–125.
- 31. Elrod, J.; Schiestl, C.; Neuhaus, D.; Mohr, C.; Neuhaus, K. Patient- and Physician-Reported Outcome of Combined Fractional CO₂ and Pulse Dye Laser Treatment for Hypertrophic Scars in Children. *Ann. Plast. Surg.* **2020**, *85*, 237–244. [CrossRef]
- Ge, X.; Sun, Y.; Lin, J.; Zhou, F.; Yao, G.; Su, X. Effects of multiple modes of UltraPulse fractional CO₂ laser treatment on extensive scarring: A retrospective study. *Lasers Med. Sci.* 2022, 37, 1575–1582. [CrossRef]
- Hultman, C.S.; Edkins, R.E.; Wu, C.; Calvert, C.T.; Cairns, B.A. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. *Ann. Plast. Surg.* 2013, 70, 521–526. [CrossRef]
- 34. Khandelwal, A.; Yelvington, M.; Tang, X.; Brown, S. Ablative fractional photothermolysis for the treatment of hypertrophic burn scars in adult and pediatric patients: A single surgeon's experience. *J. Burn Care Res.* **2014**, *35*, 455–463. [CrossRef]
- Li, N.; Yang, L.; Cheng, J.; Han, J.; Yang, X.; Zheng, Z.; Guan, H.; Hu, D. A retrospective study to identify the optimal parameters for pulsed dye laser in the treatment of hypertrophic burn scars in Chinese children with Fitzpatrick skin types III and IV. *Lasers Med. Sci.* 2021, 36, 1671–1679. [CrossRef]
- 36. Li, N.; Yang, L.; Cheng, J.; Han, J.T.; Hu, D.H. Clinical comparative study of pulsed dye laser and ultra-pulsed fractional carbon dioxide laser in the treatment of hypertrophic scars after burns. *Zhonghua Shao Shang Za Zhi* **2018**, *34*, 603–607. [CrossRef]
- Patel, S.P.; Nguyen, H.V.; Mannschreck, D.; Redett, R.J.; Puttgen, K.B.; Stewart, F.D. Fractional CO₂ Laser Treatment Outcomes for Pediatric Hypertrophic Burn Scars. J. Burn Care Res. 2019, 40, 386–391. [CrossRef]
- 38. Tan, J.; Zhou, J.; Huang, L.; Fu, Q.; Ao, M.; Yuan, L.; Luo, G. Hypertrophic Scar Improvement by Early Intervention with Ablative Fractional Carbon Dioxide Laser Treatment. *Lasers Surg. Med.* **2021**, *53*, 450–457. [CrossRef]
- Travis, T.E.; Allely, R.A.; Johnson, L.S.; Shupp, J.W. A Single-Institution Experience with Standardized Objective and Subjective Scar Evaluation While Undergoing Fractional Ablative Carbon Dioxide Laser Treatment. J. Burn Care Res. 2022, 43, 61–69. [CrossRef]
- 40. Woods, J.F.C.; Kirkham, J.; Shelley, O.P. Treatment of Postburn Scar Erythema and Dyschromia with Pulsed Dye and Q-Switched KTP Laser. *Dermatol. Surg.* **2022**, *48*, 700–702. [CrossRef]
- 41. Xie, W.G.; Lei, F.; Wang, J.; Xu, J.; Ruan, J.J.; Li, Z. Clinical effects of sequential laser treatments on early stage hypertrophic burn scars. *Zhonghua Shao Shang Za Zhi* 2018, 34, 615–623. [CrossRef]
- 42. Zuccaro, J.; Kelly, C.; Perez, M.; Doria, A.; Fish, J.S. The Effectiveness of Laser Therapy for Hypertrophic Burn Scars in Pediatric Patients: A Prospective Investigation. *J. Burn Care Res.* 2021, *42*, 847–856. [CrossRef]
- Li, N.; Yang, L.; Cheng, J.; Han, J.; Hu, D. Early intervention by Z-plasty combined with fractional CO₂ laser therapy as a potential treatment for hypertrophic burn scars. J. Plast. Reconstr. Aesthet. Surg. 2021, 74, 3087–3093. [CrossRef] [PubMed]
- Liu, H.; Shu, F.; Xu, H.; Ji, C.; Wang, Y.; Lou, X.; Luo, P.; Xiao, S.; Xia, Z.; Lv, K. Ablative fractional carbon dioxide laser improves quality of life in patients with extensive burn scars: A nested case-control study. *Lasers Surg. Med.* 2022, 54, 1207–1216. [CrossRef] [PubMed]
- Issler-Fisher, A.C.; Fisher, O.M.; Haertsch, P.A.; Li, Z.; Maitz, P.K.M. Effectiveness and safety of ablative fractional CO₂ laser for the treatment of burn scars: A case-control study. *Burns* 2021, 47, 785–795. [CrossRef] [PubMed]
- Yang, L.; Li, N.; Cheng, J.; Han, J.T.; Hu, D.H. A prospective randomized controlled clinical study on the optimal treatment interval of pulsed dye laser in treating hypertrophic scar after burn. *Zhonghua Shao Shang Za Zhi* 2021, 37, 57–63. [CrossRef]
- Tawfic, S.O.; Hassan, A.S.; El-Zahraa Sh Aly, F.; Elbendary, A.; Shaker, O.G.; AlOrbani, A.M. Fractional microneedle radiofrequency versus fractional carbon dioxide laser in the treatment of postburn hypertrophic scars. *Lasers Surg. Med.* 2022, 54, 1089–1098. [CrossRef]
- 48. Alsharnoubi, J.; Shoukry, K.E.; Fawzy, M.W.; Mohamed, O. Evaluation of scars in children after treatment with low-level laser. *Lasers Med. Sci.* 2018, 33, 1991–1995. [CrossRef]
- 49. Ebid, A.A.; Ibrahim, A.R.; Omar, M.T.; El Baky, A.M.A. Long-term effects of pulsed high-intensity laser therapy in the treatment of post-burn pruritus: A double-blind, placebo-controlled, randomized study. *Lasers Med. Sci.* 2017, 32, 693–701. [CrossRef]
- Douglas, H.; Lynch, J.; Harms, K.A.; Krop, T.; Kunath, L.; van Vreeswijk, C.; McGarry, S.; Fear, M.W.; Wood, F.M.; Murray, A.; et al. Carbon dioxide laser treatment in burn-related scarring: A prospective randomised controlled trial. *J. Plast. Reconstr. Aesthet. Surg.* 2019, 72, 863–870. [CrossRef]
- 51. El-Zawahry, B.M.; Sobhi, R.M.; Bassiouny, D.A.; Tabak, S.A. Ablative CO₂ fractional resurfacing in treatment of thermal burn scars: An open-label controlled clinical and histopathological study. *J. Cosmet. Dermatol.* **2015**, *14*, 324–331. [CrossRef]
- 52. Gaida, K.; Koller, R.; Isler, C.; Aytekin, O.; Al-Awami, M.; Meissl, G.; Frey, M. Low Level Laser Therapy—A conservative approach to the burn scar? *Burns* 2004, *30*, 362–367. [CrossRef]
- Joo, S.Y.; Cho, Y.S.; Lee, S.Y.; Seo, C.H. Regenerative effect of combined laser and human stem cell-conditioned medium therapy on hypertrophic burn scar. *Burns* 2022. [CrossRef]
- 54. Kono, T.; Ercocen, A.R.; Nakazawa, H.; Nozaki, M. Treatment of hypertrophic scars using a long-pulsed dye laser with cryogenspray cooling. *Ann. Plast. Surg.* 2005, *54*, 487–493. [CrossRef]

- El-Hoshy, K.; Abdel-Halim, M.R.E.; Dorgham, D.; El-Din Sayed, S.S.; El-Kalioby, M. Efficacy of Fractional Carbon Dioxide Laser in the Treatment of Mature Burn Scars: A Clinical, Histopathological, and Histochemical Study. J. Clin. Aesthet. Dermatol. 2017, 10, 36–43.
- 56. Elmelegy, N.G.; Hegazy, A.M.; Sadaka, M.S.; Abdeldaim, D.E. Electrophotobiomodulation in the treatment of facial post-burn hypertrophic scars in pediatric patients. *Ann. Burn. Fire Disasters* **2018**, *31*, 127–132.
- 57. Huang, Z.; Chen, Y.; Wang, P.; Zheng, D.W.; Zong, Y.L.; Lyu, G.Z. A prospective randomized controlled clinical study on the treatment of hypertrophic scar after burn by fractional carbon dioxide laser combined with autologous fat injection. *Zhonghua Shao Shang Za Zhi* **2021**, *37*, 49–56. [CrossRef]
- Kemp Bohan, P.M.; Cooper, L.E.; Lu, K.N.; Raper, D.M.; Batchinsky, M.; Carlsson, A.H.; Cancio, L.C.; Chan, R.K. Fractionated Ablative Carbon Dioxide Laser Therapy Decreases Ultrasound Thickness of Hypertrophic Burn Scar: A Prospective Process Improvement Initiative. *Ann. Plast. Surg.* 2021, *86*, 273–278. [CrossRef]
- Khedr, M.M.; Mahmoud, W.H.; Sallam, F.A.; Elmelegy, N. Comparison of Nd: YAG Laser and Combined Intense Pulsed Light and Radiofrequency in the Treatment of Hypertrophic Scars: A Prospective Clinico-Histopathological Study. *Ann. Plast. Surg.* 2020, *84*, 518–524. [CrossRef]
- 60. Lei, J.; Hao, Z.; Yu, L.; Duan, P.; Meng, Y. Clinical observation of the effects of lattice ultra pulse carbon dioxide laser combined with traditional Chinese medicine on the treatment of hyperplastic scar. *Chin. J. Burn.* **2015**, *31*, 164–167. [CrossRef]
- 61. Majid, I.; Imran, S. Fractional Carbon Dioxide Laser Resurfacing in Combination with Potent Topical Corticosteroids for Hypertrophic Burn Scars in the Pediatric Age Group: An Open Label Study. *Derm. Surg.* **2018**, *44*, 1102–1108. [CrossRef]
- Matuszczak, E.; Weremijewicz, A.; Koper-Lenkiewicz, O.M.; Kaminska, J.; Hermanowicz, A.; Debek, W.; Komarowska, M.; Tylicka, M. Effects of combined Pulsed Dye Laser and Fractional CO₂ Laser treatment of burn scars and correlation with plasma levels of collagen type I, MMP-2 and TIMP-1. *Burns* 2021, 47, 1342–1351. [CrossRef] [PubMed]
- 63. Miletta, N.; Siwy, K.; Hivnor, C.; Clark, J.; Shofner, J.; Zurakowski, D.; Anderson, R.R.; Lee, K.; Donelan, M. Fractional Ablative Laser Therapy is an Effective Treatment for Hypertrophic Burn Scars: A Prospective Study of Objective and Subjective Outcomes. *Ann. Surg.* **2021**, 274, e574–e580. [CrossRef] [PubMed]
- 64. Poetschke, J.; Dornseifer, U.; Clementoni, M.T.; Reinholz, M.; Schwaiger, H.; Steckmeier, S.; Ruzicka, T.; Gauglitz, G.G. Ultrapulsed fractional ablative carbon dioxide laser treatment of hypertrophic burn scars: Evaluation of an in-patient controlled, standardized treatment approach. *Lasers Med. Sci.* **2017**, *32*, 1031–1040. [CrossRef] [PubMed]
- 65. Tawfic, S.; Sayed, S.; Nada, A.; Manaa, D.; Shalaby, S. High-Versus Low-Density Fractional Laser in the Treatment of Hypertrophic Postburn Scars: A Randomized Clinical Trial. *Dermatol. Surg.* **2020**, *46*, e38–e44. [CrossRef]
- 66. Wang, S.; Mi, J.; Li, Q.; Jin, R.; Dong, J. Fractional microplasma radiofrequency technology for non-hypertrophic post-burn scars in Asians: A prospective study of 95 patients. *Lasers Surg. Med.* **2017**, *49*, 563–569. [CrossRef]
- Weshahy, R.H.; Aly, D.G.; Shalaby, S.; Mohammed, F.N.; Sayed, K.S. Clinical and Histological Assessment of Combined Fractional CO₂ Laser and Growth Factors Versus Fractional CO₂ Laser Alone in the Treatment of Facial Mature Burn Scars: A Pilot Split-Face Study. *Lasers Surg. Med.* 2020, 52, 952–958. [CrossRef]
- Yang, J.; Shi, S.; Wang, L.; Li, N.; Han, J.T.; Hu, D.H. A prospective randomized controlled study on the effects of compound analgesia in ultra-pulsed fractional carbon dioxide laser treatment of post-burn hypertrophic scars in children. *Zhonghua Shao Shang Za Zhi* 2022, *38*, 683–690. [CrossRef]
- 69. Zuccaro, J.; Muser, I.; Singh, M.; Yu, J.; Kelly, C.; Fish, J. Laser Therapy for Pediatric Burn Scars: Focusing on a Combined Treatment Approach. *J. Burn Care Res.* 2018, 39, 457–462. [CrossRef]
- Schäfer, M.; Werner, S. Cancer as an overhealing wound: An old hypothesis revisited. *Nat. Rev. Mol. Cell Biol.* 2008, 9, 628–638.
 [CrossRef]
- Yang, Y.; Liu, L.; Yang, R.; Ding, X.; Li, Y.; Liu, H.; Yan, H. Blood perfusion in hypertrophic scars and keloids studied by laser speckle contrast imaging. *Skin Res. Technol.* 2021, 27, 789–796. [CrossRef]
- 72. Chen, Y.; Liu, J.; Li, X. Research progress of DPL in early prevention and treatment of hypertrophic scar after burn in children. *J. Tissue Eng. Reconstr. Surg.* **2021**, *17*, 497–502. [CrossRef]
- 73. Fajardo, L.F.; Kwan, H.H.; Kowalski, J.; Prionas, S.D.; Allison, A.C. Dual role of tumor necrosis factor-alpha in angiogenesis. *Am. J. Pathol.* **1992**, *140*, 539–544.
- 74. Jaspers, M.E.H.; Stekelenburg, C.M.; Simons, J.M.; Brouwer, K.M.; Vlig, M.; van den Kerckhove, E.; Middelkoop, E.; van Zuijlen, P.P.M. Assessing blood flow, microvasculature, erythema and redness in hypertrophic scars: A cross sectional study showing different features that require precise definitions. *Burns* **2017**, *43*, 1044–1050. [CrossRef]
- 75. Li, N.; Han, J.; Hu, D.; Cheng, J.; Wang, H.; Wang, Y.; Yang, X.; Liu, J.; Li, T.; Zhao, W. Intense pulsed light is effective in treating postburn hyperpigmentation and telangiectasia in Chinese patients. *J. Cosmet. Laser Ther.* **2018**, 20, 436–441. [CrossRef]
- 76. Vrijman, C.; van Drooge, A.M.; Limpens, J.; Bos, J.D.; van der Veen, J.P.; Spuls, P.I.; Wolkerstorfer, A. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: A systematic review. *Br. J. Dermatol.* **2011**, *165*, 934–942. [CrossRef]
- 77. Cao, Y.; Huo, R.; Feng, Y.; Li, Q.; Wang, F. Effects of intense pulsed light on the biological properties and ultrastructure of skin dermal fibroblasts: Potential roles in photoaging. *Photomed. Laser Surg.* **2011**, *29*, 327–332. [CrossRef]
- Feng, Y.; Zhao, J.; Gold, M.H. Skin rejuvenation in Asian skin: The analysis of clinical effects and basic mechanisms of intense pulsed light. J. Drugs Dermatol. 2008, 7, 273–279.

- 79. Zhang, Y.; Dong, J.; Wang, C.; Yan, M.; Yao, M. Clinical effects of a combination treatment with narrow-spectrum intense pulsed light and fractional carbon dioxide laser on hypertrophic scar pruritus. *Chin. J. Burns* **2018**, *34*, 608–614. [CrossRef]
- Allison, K.P.; Kiernan, M.N.; Waters, R.A.; Clement, R.M. Pulsed dye laser treatment of burn scars. Alleviation or irritation? *Burns* 2003, 29, 207–213. [CrossRef]
- 81. Makboul, M.; Makboul, R.; Abdelhafez, A.H.; Hassan, S.S.; Youssif, S.M. Evaluation of the effect of fractional CO₂ laser on histopathological picture and TGF-beta1 expression in hypertrophic scar. *J. Cosmet. Dermatol.* **2014**, *13*, 169–179. [CrossRef]
- 82. Baroni, A.; Verolino, P. Plasma Radiofrequency Ablation for Scar Treatment. J. Clin. Med. 2021, 11, 140. [CrossRef] [PubMed]
- Jin, R.; Huang, X.; Li, H.; Yuan, Y.; Li, B.; Cheng, C.; Li, Q. Laser therapy for prevention and treatment of pathologic excessive scars. *Plast. Reconstr. Surg.* 2013, 132, 1747–1758. [CrossRef] [PubMed]
- 84. Jinping, D.; Bo, C.; Yilin, C. Research progress of laser treatment for pathological scar. *J. Tissue Eng. Reconstr. Surg.* **2016**, *12*, 141–143.
- Pan, L.; Qin, H.; Li, C.; Zhang, G.; Yang, L.; Zhang, L. Efficacy of the Neodymium-Doped Yttrium Aluminum Garnet Laser in the Treatment of Keloid and Hypertrophic Scars: A Systematic Review and Meta-analysis. *Aesthet. Plast. Surg.* 2022, 46, 1997–2005. [CrossRef] [PubMed]
- 86. Rikihisa, N.; Shimanouchi, K.; Saito, Y.; Sakai, H.; Mitsukawa, N. Carbon monoxide combined with artificial blood cells acts as an antioxidant for tissues thermally-damaged by dye laser irradiation. *Burns* **2023**, *49*, 388–400. [CrossRef]
- 87. Shu, B.; Ni, G.X.; Zhang, L.Y.; Li, X.P.; Jiang, W.L.; Zhang, L.Q. High-power helium-neon laser irradiation inhibits the growth of traumatic scars in vitro and in vivo. *Lasers Med. Sci.* 2013, *28*, 693–700. [CrossRef]
- Lev-Tov, H.; Brody, N.; Siegel, D.; Jagdeo, J. Inhibition of fibroblast proliferation in vitro using low-level infrared light-emitting diodes. *Dermatol. Surg.* 2013, 39, 422–425. [CrossRef]
- Khan, I.; Rahman, S.U.; Tang, E.; Engel, K.; Hall, B.; Kulkarni, A.B.; Arany, P.R. Author Correction: Accelerated burn wound healing with photobiomodulation therapy involves activation of endogenous latent TGF-beta1. *Sci. Rep.* 2021, *11*, 17706. [CrossRef]
- Hantash, B.M.; Ubeid, A.A.; Chang, H.; Kafi, R.; Renton, B. Bipolar fractional radiofrequency treatment induces neoelastogenesis and neocollagenesis. *Lasers Surg. Med.* 2009, 41, 1–9. [CrossRef]
- Li, J.; Wang, D.; Wang, Y.; Du, Y.; Yu, S. Effectiveness and safety of fractional micro-plasma radio-frequency treatment combined with ablative fractional carbon dioxide laser treatment for hypertrophic scar: A retrospective study. *Ann. Palliat. Med.* 2021, 10, 9800–9809. [CrossRef]
- 92. Vestita, M.; Filoni, A.; Elia, R.; Bonamonte, D.; Giudice, G. 595 nm Pulsed Dye Laser for Hypetrophic and Keloid Scars Treatment. A Randomized-Controlled Study. *Plast. Reconstr. Surg. Glob. Open* **2017**, *5*, 86–87. [CrossRef]
- Pinheiro, N.M.; Melo, P.R.; Crema, V.O.; Mendonça, A.C. Effects of radiofrequency procedure on hypertrophic scar due to burns. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 187–189. [CrossRef]
- Swanson, E. A Systematic Review of Subsurface Radiofrequency Treatments in Plastic Surgery. Ann. Plast. Surg. 2022, 89, 274–285. [CrossRef]
- 95. Mulholland, R.S. The Science and Art of Radiofrequency Assisted Lipocoagulation (RFAL) in Body Contouring Surgery. In *The Art of Body Contouring*; Books on Demand: Paris, France, 2019.
- 96. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 2021, 372, n71. [CrossRef]
- 97. OCEBM Levels of Evidence Work Group. The Oxford Levels of Evidence 2. Oxford Center of Evidence Based Medicine. Available online: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence (accessed on 20 January 2023).
- Cooper, L.E.; Nuutila, K.; Kemp Bohan, P.M.; Diaz, V.; Batchinsky, M.; Carlsson, A.H.; Cancio, L.C.; Chan, R.K. Analysis of the Utility of CO₂ and Pulse-Dye Lasers Together and Separately in the Treatment of Hypertrophic Burn Scars. *Ann. Plast. Surg.* 2022, 89, 166–172.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.